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by 
Elizabeth W. White 
Under the Direction of Dr. W. David Wilson 
ABSTRACT 
Structure-specific recognition of nucleic acids is a promising method to reduce 
the size of the recognition unit required to achieve the necessary selectivity and binding 
affinity for small molecules. It has been demonstrated recently that G-quadruplex DNA 
structures can be targeted by organic cations in a structure-specific manner. Structural 
targets of quadruplexes include the planar end surfaces of the G-tetrad stacked columns 
as well as four grooves. The significant structural differences between quadruplex DNA 
and duplex DNA make quadruplex DNA a very attractive target for highly selective, 
structure-specific drug design. We have used a variety of biophysical techniques 
including circular dichroism, surface plasmon resonance, thermal melting and absorbance 
spectroscopy to investigate small molecules that can selectively bind to the ends of 
human telomeric DNA as well as the ends of the G-quadruplex structure formed by the 
purine-rich promoter region of the c-MYC oncogene. We have also screened a library of 
heterocyclic diamidines, and identified one that binds selectively in the grooves of human 
telomeric quadruplex DNA. This compound is an excellent starting point for the design 
of new anti-cancer and anti-parasitic compounds with high affinity and selectivity for 
human telomeric DNA. 
INDEX WORDS:  Molecular recognition, Quadruplex DNA, Circular dichroism, 
Surface plasmon resonance, Telomeres, Telomerase inhibitors, i-
motif, c-MYC oncogene, G-quartet
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Chapter 1 
Overview 
Introduction 
Specific recognition of double helical sequences of base pairs in DNA, for 
example, by transcription control proteins [1] and designed synthetic molecules [2, 3], 
has been thoroughly studied and many sequence-specific recognition complexes are now 
characterized in molecular detail. Therapeutic intervention or control of cellular function 
through specific recognition of a cellular duplex DNA sequence requires interaction with 
a large number of base pairs. This is routinely accomplished by cellular proteins but is 
more difficult to achieve with relatively small synthetic compounds that must have 
properties that allow them to pass through barriers including cell membranes in order to 
bind to DNA. Incorporating nucleic acid structure into the recognition motif, however, is 
a promising method to reduce the size of the recognition sequence required to gain the 
necessary specificity. Specific recognition of RNA structures by small molecules that 
interact with only a few bases or base pairs, for example, is well established for 
aminoglycoside antibiotics that target ribosomal RNA [4-6]. The recent discovery of 
small metabolites and analogs that bind specifically to RNA riboswitch structures is now 
a demonstrated method for specific control of translation [7]. Selection methods that 
yield nucleic acids that are capable of highly specific binding to small molecules provide 
an additional example of recognition by structure-specific motifs [8]. Examples of 
structure-specific targeting are also emerging for selective recognition of DNA. The 
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mitochondrial kinetoplast DNA of kinetoplastid eukaryotic parasites, which cause serious 
diseases that affect millions of people, for example, has a complex structure that is 
composed of a few large circular DNAs in an interlocked, catenated array with thousands 
of minicircular DNAs [9-11]. The minicircular DNAs have phased AT sequence tracts 
that bend the DNA duplex [12] and provide an optimum sequence-structure target for 
drug design [13]. 
Another structural target of interest is four-stranded quadruplex DNA. Guanine-
rich sequences, which are capable of forming quadruplex structures, are present in 
biologically significant regions of the genome including telomeres [14], immunoglobulin 
switch regions [15], the transcriptional regulatory regions of a number of genes such as 
the insulin gene [16], and also the promoter regions of certain oncogenes, such as c-MYC 
[17, 18]. Cytosine-rich DNA, such as found in the complementary DNA strand of 
sequences that form G-quadruplexes, has also been shown to form four-stranded 
structures in vitro, known as i-motif DNA. The key structural feature of the G-quadruplex 
is a series of stacked guanine tetrads held together in a coplanar cyclic array by 
Hoogsteen and Watson-Crick hydrogen bonds (Figure 1.1). The quadruplex is also 
stabilized through π-π stacking interactions of the stacked tetrads as well as by 
coordination with cations located between or within the tetrads. G-quadruplexes have 
been shown to form a variety of secondary structures, which depend on the sequence, 
strand stoichiometry, and sometimes the nature of cations present. These structures can 
be characterized as parallel, or antiparallel, depending on strand orientation. G-
quadruplexes may be intermolecular, consisting of four DNA strands (tetrameric), or two  
hairpin strands (dimeric), or may be intramolecular, consisting of a folded single strand. 
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Some examples of quadruplex conformations are shown in Figure 1.2. The significant 
structural differences between quadruplex DNA and duplex DNA make quadruplex DNA 
a very attractive target for highly selective, structure-specific drug design. Three 
quadruplex-forming sequences that have been studied as structure-specific targets for 
quadruplex-interactive compounds include human telomeric DNA, i-motif DNA formed 
by the pyrimidine-rich strand of the c-MYC oncogene, and G-quadruplexes formed by 
the purine-rich strand of the c-MYC oncogene.  
Telomeres 
Telomeres are regions of non-coding DNA located at the ends of eukaryotic 
chromosomes in organisms as diverse as trypanosomes and humans. Their function is to 
protect the ends of the chromosomes from erosion, end-end fusion, and to aid in 
chromosomal alignment during recombination. Human telomeres consist of a 5-15 
kilobase double-stranded region with one purine-rich strand and one pyrimidine-rich 
stand. At the extreme 3’ end, the purine-rich strand exists as a single-stranded overhang 
about 200 bases long. The telomeric sequence varies depending on the organism. In 
humans and other vertebrates, telomeres consist of tandem T2AG3 repeats. The human 
telomere sequence has been shown to adopt a G-quadruplex conformation in vitro under 
physiological conditions [19, 20]. The discovery of proteins such as transcription factors, 
nucleases and helicases that can bind to and even promote the formation of telomeric 
quadruplexes suggests that these structures may exist in vivo under certain conditions 
[21-23]. A very exciting recent finding by Boussin and coworkers is that a radiolabeled 
G-quadruplex binding ligand accumulated in nuclei of cultured cells and preferentially 
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bound to the terminal regions of the chromosomes, suggesting that G-quadruplexes do 
exist in vivo and are accessible to drugs [24].  
Each time a cell divides, DNA polymerase is unable to replicate the extreme end 
of the 3’strand of the chromosome, since it is the lagging strand during replication. This 
“end replication problem” results in shortening of the telomere by about 30-200 bases per 
cell doubling. After 60-70 rounds of cell replication, the telomeres reach a critical length, 
and are no longer able to form secondary structures. The cells enter a non-dividing state 
called senescence either by activating p53 or by inducing the p16/RB pathway, which 
leads to apoptosis and eventually cell death [25]. However, in 85-90% of cancer cells the 
reverse transcription enzyme telomerase is activated [26]. The enzyme is also active in 
eukaryotic parasites such as trypanosomes and leishmania. This enzyme is inactive in 
most normal somatic cells, providing a potentially very specific target for the treatment of 
cancer and parasitic disease. In humans telomerase adds T2AG3 repeats to the telomere 
ends, which balances telomere shortening during cell division. The result is that telomere 
length is maintained, contributing to immortality of the cancer cells. Telomerase consists 
of an 11 base RNA template and an hTERT catalytic subunit with reverse transcriptase 
activity. Telomerase inhibition has been studied as an anti-cancer strategy. Targets for 
telomerase inhibition include the hTERT catalytic subunit, targeted by reverse 
transcriptase inhibitors and dominant negative hTERT constructs [27-32]. The RNA 
template has also been targeted using antisense oligonucleotides [33, 34] as well as 
hammerhead ribozymes [35, 36]. Our focus is on the telomere primer rather than the 
enzyme itself. Telomerase requires the telomere primer to be single stranded. The 
formation of higher-ordered structures such as G-quadruplexes, prevents hybridization of 
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the telomerase RNA template onto the primer and thus inhibits telomerase activity 
through an indirect topological mechanism [37]. Stabilization of the quadruplex 
conformation of telomeres, such as by binding with a small molecule, has been shown to 
inhibit telomerase activity. The development of small molecules that can selectively bind 
to and stabilize the G-quadruplex conformation of the telomere is therefore a current area 
of interest in anti-cancer drug design.  
In eukaryotic parasites the telomere and telomerase is essential for all of the 
functions described above but also for additional gene control mechanisms. The enzyme 
telomerase is found in disease-causing unicellular protozoan parasites, such as 
Plasmodium, Trypanosoma, and Leishmania species [38, 39]. The telomeres of these 
organisms consist of the same sequence of tandem T2AG3 repeats as in human telomeres. 
These protozoa undergo very rapid cell division, but because telomere shortening is 
compensated for by telomerase, these cells can undergo an unlimited number of cell 
divisions, much like cancer cells. The protozoan pathogens cause such diseases as 
malaria and African sleeping sickness and are responsible for millions of deaths each 
year. The few available antiprotozoan therapies suffer from problems such as drug 
resistance and severe toxicity to the host. Telomerase inhibition through stabilization of 
the quadruplex conformation of the telomere offers an attractive, selective target for the 
design of agents which may impair the proliferation of these protozoa with decreased 
cytotoxicity and drug resistance. 
Promoter Region of c-MYC Oncogene 
Emerging evidence for the involvement of G-quadruplex structures in cellular 
processes such as transcriptional control of the c-MYC oncogene has stimulated the 
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development of drugs that have selectivity for different G-quadruplex structures for the 
purpose of controlling gene regulation. The promoter regions of some important genes, 
such as the insulin gene, c-MYC, PDGF, HER-2/neu, c-MYB, the human and chicken β-
globin genes, the rat preproinsulin II gene, adenovirus serotype 2, and retinoblastoma 
susceptibility genes, have been found to contain sequences that have the ability to form 
G-quadruplex structures under physiological conditions [18, 40-44]. Direct evidence for 
the involvement of G-quadruplexes in transcriptional control has been obtained only for 
c-MYC and the insulin gene. The protein product of c-MYC activates telomerase and 
facilitates cell growth by altering the activity of certain transcription factors [45-47]. 
Overexpression of c-MYC results in increased cellular proliferation in a variety of human 
and animal malignanices, including cancers of the colon, breast, cervix, and lungs, as 
well as B and T cell lymphomas, osteosarcomas, glioblastomas and myeloid leukemias 
[48-51]. A 27-bp sequence located -142 to -115 bp upstream of the P1 promoter of c-
MYC, known as the Nuclease Hypersensitivity Element, (NHEIII1), controls up to 90% 
of the transcriptional activity of the gene, making it an attractive target for anti-cancer 
drug design [52-55]. This DNA sequence contains a non-coding purine-rich strand, and 
its complementary pyrimidine-rich coding strand. The NHEIII1 exists as a duplex 
structure, but can interconvert in a slow equilibrium with both unwound and quadruplex 
structures with the aid of an accessory factor with helicase activity known as NM23-H2. 
The conformation of the purine-rich strand has been proposed to act as a transcriptional 
switch [17]. When the NHEIII1 is in either the duplex or unwound single-stranded form, 
the gene is transcriptionally active and expression occurs. With the aid of the accessory 
protein, the purine-rich strand can form a highly dynamic mixture of four parallel G-
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quadruplex loop isomers, all of which have been shown to act as transcriptional 
repressors and silence gene expression [56]. The 1:2:1 loop isomer is predominant, and 
the NMR structure has been solved for this isomer [57]. This transcriptionally silent state 
must be remodeled back to the duplex state with the aid of the accessory protein for 
transcription to occur. Small molecules which can bind to one of these transcriptionally 
silent paranemic DNA forms and prevent the conformational change back to the duplex 
state may act as transcriptional repressors, preventing expression of this oncogene, thus 
making this DNA element an attractive target for structure-specific anti-cancer drug 
design. 
i-motif DNA 
Under acidic pH conditions, cytosine-rich DNA sequences are capable of forming 
four-stranded quadruplex structures known as i-motif DNA. The i-motif structure is 
comprised of two parallel-stranded duplexes containing hemiprotonated C·C+ mismatch 
base pairs (Figure 1.3). Protonation occurs at the N3 of one cytosine, which allows three 
hydrogen bonds with non-protonated cytosine. The two duplexes are zipped together in 
an antiparallel orientation, with the C·C+ base pairs from each duplex intercalated 
between each other (Figure 1.3). Like G-quadruplexes, i-motif DNA can fold into 
monomeric, dimeric or tetrameric structures, depending on the sequence. However, the 
conformation of i-motif is not cation-dependent as is the case with G-quadruplex DNA, 
since there is no cation binding site. Sequences capable of forming i-motif structures are 
found throughout the genome, including in telomeres and the regulatory regions of genes 
such as the retinoblastoma susceptibility gene, myeloid-specific genes and the c-MYC 
oncogene [18, 58-60].  
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I-motif DNA has not received as much attention as G-quadruplex DNA as a 
potential drug target. The belief that these structures may not exist in vivo under  
physiological conditions has hindered research in this area. While the structure of G-
quadruplex DNA is not significantly affected by changes in pH [61], i-motif 
conformation is pH sensitive and is favored by slightly acidic pH conditions. CD studies 
of C-rich oligomers have shown that sequences that form i-motif structures at low pH 
unfold as the pH is increased to 7.4 [61]. Although there is no direct evidence of a 
biological role for i-motif DNA, or that i-motif structures exist in vivo, proteins have been 
discovered which are capable of binding to i-motif sequences [62-64]. I-motif recognition 
proteins that have been recently discovered include ST-1 of Trypanosoma brucei, 
qTBP42 of rat hepatocytes and hnRNP K and ASF/SF2, which bind to the pyrimidine-
rich strand of human telomeres [64-66].  It has also been hypothesized that i-motif 
formation could be aided in vivo by superhelical stress due to chromatin assembly [67]. 
Small molecules have been shown to promote G-quadruplex formation under unfavorable 
conditions (such as the absence of added cation) [68, 69] so, it seems possible that some 
small molecules could induce formation of i-motif structures under physiological 
conditions as well. These factors suggest that i-motif structures formed by pyrimidine-
rich DNA sequences may indeed exist in vivo, have biological function, and may serve as 
a potential drug design target for cancer and other diseases. 
Objectives of this Dissertation 
Discovery and design of compounds that target G-quadruplex structures in DNA 
is a relatively new area that is now being rapidly driven by the desire to discover new 
anti-cancer drugs and targets. The majority of compounds that have been shown to bind 
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to quadruplex DNA are planar, aromatic compounds that bind via external end-stacking 
to the G-quartet on either one end or both ends of the quadruplex. These compounds, 
which include anthraquinones, cationic porphyrins, acridines, perylenes, macrocycles and 
related compounds have large aromatic planar chromophores that mimic the planar 
surface of the G-quartets [70-73]. These molecules bind non-covalently through 
electrostatic, van der Waals, and π-orbital overlap interactions, and generally also interact 
with the loop bases. Since essentially all known quadruplex DNA binders are based on or 
derived from prototype duplex intercalators, many exhibit little selectivity for quadruplex 
over duplex structures. These types of molecules exhibit non-selective binding to many 
sites, leading to the cytotoxic side effects generally associated with chemotherapy, such 
as nausea vomiting, hair loss, and heart and kidney damage. Binding to non-targeted 
duplex sequences can also result in significant loss of compound. Since potential 
quadruplex-forming sequences are common in the genome, selectivity for a particular 
quadruplex structure over other quadruplexes is also a concern in the design of 
quadruplex-binding compounds. Binding to non-targeted quadruplex sequences results in 
compound loss and may have unintentional effects on regulation of non-targeted genes. 
Thus, there is a need for new classes of compounds that can bind to quadruplex DNA via 
novel binding modes, with high affinity and with selectivity over duplex and other 
quadruplex DNA.  
The goal of this dissertation is to use biophysical methods to investigate the 
interactions between a series of small molecules with their respective quadruplex targets 
in order to gain insight into how quadruplex DNA can be effectively targeted in a 
structure-specific manner, and to provide the basis of design of new molecules which will 
  10   
bind with improved affinity and selectivity over current therapeutics in order to provide 
enhanced telomerase inhibition and oncogene transcriptional repression for treating 
cancer and microbial (e.g. protozoal) infections with fewer side effects.  
Chapter 2 describes the screening of a series of commercially available 
compounds as well as a library of heterocyclic diamidines in order to identify compounds 
that bind to human telomeric DNA. A bifuryl compound, DB 832, was identified as a 
possible quadruplex DNA groove binder and chosen for further study, as presented in 
Chapter 3. Biophysical techniques including ITC, UV-Vis absorbance spectroscopy, and 
photocleavage were used to investigate the binding mode, and location of the binding site 
of DB 832 with human telomeric DNA. Chapter 4 describes the use of circular dichroism 
to investigate the binding of DB 832 with other DNA sequences to evaluate its selectivity 
for certain DNA structural types. Derivatives and analogues of DB 832 are also studied in 
order to develop initial structure-activity relationships to better understand how this 
compound binds to quadruplex DNA, and to aid in the future design of new molecules 
with improved binding and selectivity. Chapter 5 characterizes the interactions of a series 
of modified porphyrin compounds with both human telomeric DNA as well as a promoter 
region of the c-MYC oncogene using surface plasmon resonance. Chapter 6 examines a 
fluoroquinolone derivative that has been shown to have potential use as an anti-cancer 
therapeutic. Surface plasmon resonance is used to determine if this compound is 
quadruplex-interactive, and if so, to determine which quadruplex structure is the likely 
target for this compound. 
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Figure 1.1 G-quartet structure. The Hoogsteen face of each guanine is hydrogen bonded 
to the Watson-Crick face of the adjacent guanine, resulting in a coplanar array. 
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Figure 1.2 Examples of inter- and intramolecular quadruplex DNA conformations. 
structure-specific targets for quadruplex-interactive compounds.  
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Figure 1.3 Structure of hemiprotonated C·C+ mismatch base pair as found in i-motif 
DNA (top) and intercalated base pairing scheme of i-motif DNA (bottom) 
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Chapter 2 
Search for Compounds that Bind to Quadruplex Grooves 
Introduction 
 Stabilization of the quadruplex conformation of telomeres, such as by binding 
small molecules, has been shown to be an effective method to inhibit telomerase activity 
[1-9]. The development of small molecules that can selectively bind to and stabilize the 
G-quadruplex conformation of the telomere is therefore a current area of interest in 
anticancer as well as antiparasitic drug design. Compounds that have been shown to bind 
to quadruplex DNA have traditionally been planar, aromatic compounds that bind via 
external end-stacking to the G-quartet on either one end or both ends of the quadruplex 
[1-8]. These compounds, which include anthraquinones, cationic porphyrins, acridines, 
macrocyclic compounds and analogs have planar aromatic surface areas that mimic the 
large planar surface of the G-tetrads in quadruplex DNA [10-13]. Since essentially all 
known quadruplex DNA binders are based on, or derived from duplex intercalators, many 
exhibit little selectivity for quadruplex over duplex structures and this can result in 
nonspecific cytotoxicity. Increasing the selectivity of telomerase inhibitors for their 
quadruplex targets is an important focus of research. 
 Groove binding has been a useful way to selectively recognize duplex DNA with 
relatively low nonspecific toxicity [14-19], but groove binding is an under-exploited 
design mode with DNA quadruplexes. The structural differences between duplex and 
quadruplex DNA grooves offer an attractive strategy for development of compounds to 
  24   
differentiate between these two structures. Since groove dimensions vary according to the 
type of quadruplex [20], groove binding also offers the opportunity for obtaining 
increased selectivity for a particular quadruplex structure. Groove-binding has been 
proposed as a binding mode for some small molecule/ quadruplex DNA combinations. 
Shafer et al. obtained spectroscopic data suggesting that the dye 3,3’-
diethyloxadicarbocyanine (DODC) binds in the quadruplex grooves of a dimeric hairpin 
G-quadruplex [21]. Satellite hole spectroscopy studies support the groove-binding model 
for this particular compound/DNA pair [22, 23]. Electrospray mass spectrometry 
fragmentation patterns upon ionization also indicate that the carbocyanine dye DTC binds 
in the quadruplex grooves [24]. However, in spite of extensive experiments with 
quadruplex DNA, no compounds to date have been found which bind to the grooves of 
the intramolecular human or parasite telomeres or to oncogene control quadruplexes. 
Thus, although G-quadruplex end-stacking is a well-established and documented 
recognition mode, binding in the G-quadruplex grooves is an area that lacks adequate 
models for drug design and development. 
 Since typical screening techniques such as thermal denaturation and surface 
plasmon resonance (SPR) are not capable of distinguishing between groove binding and 
intercalating-type end-stacking interactions, an alternate technique such as circular 
dichroism (CD) must be employed to evaluate the binding mode. Circular dichroism 
pattern recognition has been used as a technique for determination of binding mode with 
duplex DNA-binding compounds [25]. Induced circular dichroism (CD) signals of 
molecules bound to duplex DNA have provided a very powerful method to distinguish 
intercalation-stacking type interactions from groove binding [25]. Non-chiral molecules 
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exhibit no CD signal in solution. However, when an achiral ligand binds tightly to a 
chiral host, such as DNA, a CD signal is induced in the wavelength region corresponding 
to the absorbance of the bound compound. Intercalating compounds usually produce 
negative induced CD signals or very small positive signals. Groove binding is generally 
indicated by the presence of a large positive induced CD signal upon titration of 
compound into duplex DNA. However, pattern recognition of induced CD signals has not 
been established for small molecules binding to quadruplex DNA.  
Circular dichroism is also useful for evaluation of small molecule binding to 
quadruplex DNA because it not only can yield information about mode of binding, but 
can also provide information about the conformation of the DNA. Due to the 
polymorphism of quadruplex DNA, small molecules may trap out certain quadruplex 
conformations out of a mixture, or even induce a conformational change in the 
quadruplex structure. Since it has been proposed that some conformations of quadruplex 
DNA may be more biologically relevant than others [26, 27], it is especially important to 
have information about the conformation of the DNA. 
Stacked species are of particular interest for recognition of quadruplexes since 
studies with duplex DNAs show that compounds that bind as stacked dimers have 
increased binding affinity and selectivity over similar compounds that bind as monomers 
[14, 15, 17, 18, 28-30]. Similar stacking in the grooves of quadruplex DNA structures 
would appear to be a favorable way to selectively recognize quadruplexes with optimum 
interactions, perhaps employing an induced fit component, between the stacked 
heterocycles and the G bases of the quadruplex tetrads. 
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To initiate a search for compounds that can bind as stacked species to quadruplex 
DNA grooves we have used CD spectroscopy and induced CD signals to distinguish end 
stacking from stacked groove complexes. For quantitative comparison of binding 
affinities of quadruplex-binding agents under a defined set of conditions, we have used 
SPR. SPR is a powerful technique to monitor molecular reactions in real time and has 
been used previously to study the interaction of compounds with the G-quadruplex 
formed in the human telomeric sequence [12, 13]. This method uses very little material 
and is applicable to a very large variety of small molecules with quite different 
properties, binding modes and affinities.  
We report CD results for a number of compounds of quite different structure, 
including a cyanine dye that exhibits CD spectral characteristics consistent with groove 
binding as a stacked species. Based on the CD results, a library of diamidines synthesized 
by Boykin and coworkers at Georgia State University was screened against the human 
telomeric sequence using circular dichroism. Diamidines were chosen because they have 
favorable cell uptake properties and low general toxicity, making them ideal for possible 
therapeutic use. Of the compounds evaluated, DB 832 was identified as a potential 
quadruplex groove-binder and selected for further study. This molecule serves as a 
paradigm to show that the grooves of the human telomere can indeed be targeted and also 
serves as the starting point for the design of new molecules that may have therapeutic use 
as anti-cancer or anti-trypanosomal agents. 
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Materials and Methods 
Sample Preparation 
The oligonucleotides d[AG3(T2AG3)3] and d(AG3TG4AG3TG4A) were purchased 
with HPLC purification from Midland Certified Reagent Company. The G-quadruplex 
DNA samples were dissolved in buffer to the desired concentrations, heated to 85 0C and 
cooled slowly to insure the folding of the quadruplexes prior to each experiment. The 
concentration of each DNA sample was determined spectrophotometrically at 260 nm 
using the nearest neighbor extinction coefficient at 80°C and extrapolated to 20°C. Stock 
solutions containing 1 mM each of compound were prepared in double distilled water and 
diluted to working concentrations immediately before use with buffer. Ethidium bromide, 
distamycin A, neomycin, thionin, chromomycin A3, mithramycin, DODC, DOC, DTDC 
and DTC were obtained from Sigma Aldrich. fImImIm was synthesized by the Lee group 
at Furman University [31]. The synthesis of all DB compounds will be described 
elsewhere. 
CD Measurements 
CD measurements were performed at 20°C in a 10 mM HEPES buffer (pH 7.4) 
containing 3 mM EDTA and 50 mM KCl, NaCl or 50 mM KCl plus 50 mM MgCl2. For 
CD measurements obtained in the presence of 50 mM LiCl or in the absence of added 
salt, a 10 mM TRIS buffer containing 3 mM EDTA acid and pH adjusted to 7.4 using 
TRIS was used. CD spectra were recorded using a Jasco J-810 spectrapolarimeter in a 1-
cm cell using an instrument scanning speed of 50 nm/min with a response time of 1 s. 
The spectra were averaged over four scans. Appropriate amounts of compound were 
added sequentially to increase the molar ratio. A buffer baseline scan was collected in the 
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same cuvette and subtracted from the average scan for each CD experiment. Data 
manipulation and plotting was performed using the program Kaleidagraph version 3.6. 
Immobilization of DNA and Biosensor SPR Experiments 
Biosensor SPR experiments were performed with a four-channel BIAcore 3000 
optical biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips (BIAcore 
SA with linked streptavidin). The concentration in all cases refers to the strand 
concentration, which is also the quadruplex concentration. The chips were prepared for 
use by conditioning with three to five consecutive 1 min injections of 1 M NaCl in 50 
mM NaOH followed by extensive washing with buffer. 5'-Biotinylated DNA samples (25 
nM) in HBS buffer were immobilized on the flow cell surface by noncovalent capture as 
previously described [17, 18, 31, 32]. Three flow cells were used to immobilize DNA 
oligomer samples, and a fourth cell was left blank as a control. Interaction analysis was 
performed by steady-state methods with multiple injections of different compound 
concentrations over the immobilized DNA surface at 25 ºC. DNA-binding experiments 
were performed in sterile filtered and degassed HBS buffers: 0.01 M HEPES, (pH 7.4), 3 
mM EDTA, and 0.005% surfactant P20 with 0.2 M KCl. Compound solutions were 
prepared in the desired buffer by serial dilutions from stock solution and injected from 7 
mm plastic vials with pierceable plastic crimp caps (BIAcore, Inc.) at a flow rate of 25 
µL/min. To remove any remaining bound compound after the dissociation phase of the 
sensorgram, a low-pH glycine regeneration buffer was used (10 mM glycine at pH 2). 
The baseline was then reestablished, and the next compound concentration sample was 
injected.  
  29   
The instrument response (RU) in the steady-state region is proportional to the 
amount of bound drug and was typically determined by linear averaging over a 10-20 s or 
longer time span, depending on the length of the steady-state plateau. The predicted 
maximum response per bound compound in the steady-state region (RUmax) was 
determined from the DNA molecular weight, the amount of DNA on the flow cell, the 
compound molecular weight, and the refractive index gradient ratio of the compound and 
DNA, as previously described [17, 18, 31, 32]. The number of binding sites was 
estimated fitting plots of RU versus Cfree. These methods can also be used to determine an 
empirical RUmax value. The RUmax value is required to convert the observed response 
(RU) to the standard binding parameter r (moles of drug bound per moles of DNA) 
r = RU/RUmax 
 
which is useful for comparison of a compound binding to different DNAs. To obtain the 
affinity constants, the data were fitted to the following interaction model using 
Kaleidagraph for nonlinear least-squares optimization of the binding parameters: 
 
r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2) 
 
where K1 and K2 are equilibrium constants for two types of binding sites and Cfree is the 
concentration of the compound in equilibrium with the complex and is fixed by the 
concentration in the flow solution. For a single dominant binding site model, K2 is equal 
to zero.  
  30   
Results and Discussion 
Duplex DNA Binders 
To develop a paradigm for groove-binding, a series of compounds that bind to 
duplex DNA were evaluated. The compounds cover a range of structural types and each 
compound interacts with duplex DNA in a different manner. The compounds were 
evaluated against the human telomere using circular dichroism to determine if any 
unusual induced CD signature existed which could be used for pattern recognition in the 
screening of potential quadruplex DNA-binding compounds. As a control for the CD 
analysis, a titration was first performed with a well-characterized quadruplex end-
stacking compound, ethidium [33, 34]. With this compound there are no significant 
induced signals as seen in Figure 2.1. 
Distamycin binds as a stacked dimer to the minor groove of AT-rich duplex DNA 
sequences. It has previously been suggested distamycin may bind to the grooves of 
certain quadruplex DNA sequences [21-24, 35], although more recent NMR results 
indicate that distamycin stacks on the ends of quadruplexes [36]. The CD spectra of 
human telomeric DNA does not show any change when titrated with distamycin (Figure 
2.2) suggesting that it binds very weakly, if at all to this sequence. SPR results confirm 
the weak binding (Ka <105 M-1) to the human telomere and binding is likely to only be 
seen in high concentration experiments such as NMR.  
Since the minor groove binder, distamycin, does not bind to the grooves of the 
human telomere, neomycin, an aminoglycoside antibiotic that binds in the major groove 
of DNA duplexes was studied to see if it binds to the human telomere. Figure 2.3 shows 
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the CD spectra of neomycin titrated into human telomeric DNA. Like distamycin, this 
compound does not appear to interact with human telomeric DNA. 
The minor-groove binding polyamide fImImIm (Figure 2.4) selectively binds to 
GC-rich duplex DNA through hydrogen binding interactions [31]. The CD spectra of 
fImImIm titrated into human telomeric DNA do not reveal any significant quadruplex 
interactions. It seems unlikely that traditional polyamides will interact significantly with 
telomere, and probably other, DNA quadruplex structures due to the differences in 
geometry of the grooves.  
Thionin is a cationic dye that has been shown to intercalate with duplex DNA. It 
can form a dimer and has been shown to bind to some quadruplex sequences and exhibit 
exciton splitting in the induced region [37]. In these cases, it is believed to stack on the 
quartet ends. The CD spectra of thionin titrated into the human telomeric sequence is 
shown in Figure 2.5. There is no change in the CD spectra in either the DNA region or 
the induced region up to a 4:1 ratio, indicating that thionin likely does not bind to this 
quadruplex sequence. 
Chromomycin A3 and mithramycin are commercially available aureolic acid 
antibiotics. Chromomycin A3 is produced from Streptomyces grieus, while mithramycin 
is produced from Streptomyces plicatus. These compounds bind as Mg2+-mediated 
dimers through hydrogen bonding with 2-amino groups on guanines in the minor grooves 
of GC-rich sequences [38, 39]. They disrupt replication and transcription processes 
through inhibition of DNA and RNA polymerases [38-40]. It was speculated that these 
compounds may bind to quadruplex grooves since they selectively recognize the grooves 
of guanine-containing sequences. CD titrations of chromomycin added to human 
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telomeric DNA and the c-MYC sequence in the presence of 50 mM K+ and 50 mM Mg2+ 
are shown in Figures 2.6 and 2.7, respectively. Chromomycin and mithramycin are chiral, 
and therefore optically active. Both compounds produce CD signals even in the absence 
of DNA. Because these compounds have absorbance bands in the visible region of the 
spectrum as well as in the near-UV, where DNA absorbs, the signals of these compounds 
overlap with the CD signal from the DNA, which may mask any changes in the CD 
spectrum of the DNA. The chirality of these compounds therefore makes it difficult to 
ascertain whether any CD signal is being induced or even whether the compound is 
binding to the DNA at all. However, since there appears to be a significant difference in 
the c-MYC and human telomere spectra when titrated with chromomycin A3, it suggests 
that this compound may be selective for one of these DNAs. 
The Mg2+-mediated mithramycin dimer is more flexible than the chromomycin 
dimer due to a high degree of plasticity in its trisaccharide segment [40, 41].  This 
flexibility makes it less sensitive to groove width which may result in better binding to 
quadruplex sequences. This is supported by the CD spectra of mithramycin titrated into 
the human telomeric sequence (Figure 2.8) and the c-MYC sequence (Figure 2.9). The 
much larger magnitude of CD signal with the human telomeric sequence as well as the c-
MYC sequence suggests that mithramycin may interact more favorably with 
quadruplexes than chromomycin does. Spectra were also obtained for mithramycin with 
the human telomere in the presence of sodium (Figure 2.10) as well as lithium (Figure 
2.11) to see if the starting conformation of the DNA had any effect on binding. The 
human telomere has an antiparallel basket-type structure in sodium [42], and the structure 
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is unfolded in the presence of lithium [43]. The spectra are of similar shape and 
magnitude regardless of the starting conformation of the human telomeric DNA. 
To differentiate between the contribution to the CD signal due to binding and the 
inherent CD signal of mithramycin, the highest concentration spectrum in Figure 2.8 was 
shown on the same graph as the CD signal of identical amount of mithramycin in the 
absence of DNA. The difference in these curves suggests that at least some of the CD 
signal is due to actual binding interactions, or possibly a change in the spectral properties 
of mithramycin over the duration of the titration. To determine if the large change in CD 
signal upon titration was due to any time-dependent change in the spectral properties of 
mithramycin, a CD spectrum was obtained for mithramycin in the absence of DNA, and 
the same sample was run again after a period of one hour (Figure 2.13). There is no 
change in the CD signal at any wavelength, suggesting that the CD signal of mithramycin 
is not time-dependent and that binding between mithramycin and the human telomere 
may be occurring. However, SPR results show that mithramycin does not bind to any 
significant extent with the human telomere as demonstrated by the sensorgrams shown in 
Figure 2.14. Although the results with chromomycin and mithramycin are interesting, the 
problems with the inherent circular dichroism of the compounds makes it difficult to 
study, and even if these compounds do bind in the grooves of quadruplex DNA, they are 
not useful as a paradigm for groove-binding.  
Cyanine derivatives, which form stacked complexes in the minor groove of 
duplex DNAs, exhibit strong exciton splitting in their induced CD spectra with duplexes 
[29, 30, 44]. CD titrations were performed on the intramolecular human telomere DNA 
with four different cyanine compounds: DODC, DOC, and their sulfur analogs, DTDC 
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and DTC (Figures 2.15-2.18).  Although each of the cyanines appears to interact with the 
human telomere, DODC appears to have the strongest interaction. The titration spectra 
for DODC show a strong induced CD signal in the DODC absorption region (Figure 
2.15). Exciton splitting in the induced spectra indicates that DODC binds to the 
quadruplex grooves as one or more stacked species. Since DODC is also the only one of 
the four compounds that is water soluble, it was chosen for further study by surface 
plasmon resonance to quantify the binding of DODC with the intramolecular human 
telomeric DNA sequence. The binding curve is shown in Figure 2.19. Because DODC 
has an absorbance band that overlaps with the light used by the SPR instrument, an 
enhancement of signal occurs which results in artificially high response unit values. 
Therefore, the stoichiometry of binding cannot be determined by RUmax from the SPR 
experiments. Since DODC dimerizes in solution, even at the low concentrations used in 
SPR, it can be assumed that binding is occurring as a series of dimers. Since the binding 
curve is sigmoidal in shape, it suggests that two (or more) dimers are binding to the 
sequence with positive cooperativity. For the analysis of binding constants, we assume 
that DODC is binding as a set of two dimers. A fit of the data gives the equilibrium 
binding constants for each of the two dimers to be K1 = 3.3 x 104 M-1 and K2 = 2.2 x 106 
M-1. The positive cooperativity suggests that the binding of the first dimer may cause a 
distortion to one of the other grooves that makes it a better binding site for the second 
dimer. 
Screening of Library of Heterocyclic Diamidines 
 The DODC results are quite exciting and indicate that compound stacking in the 
quadruplex grooves is a promising approach for the design of highly selective 
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quadruplex-targeting agents. The results also indicate that the presence of an induced 
exciton CD signal can be used as a method to distinguish among binding modes. Boykin 
and coworkers have designed a series of unfused aromatic heterocycles with terminal 
amidine substituents that are excellent groove-binding agents with duplex DNA [45]. The 
compounds also get into cells and are promising antiparasitic drug development 
candidates [19]. Over 150 compounds from this library were screened against the 
intramolecular human telomeric sequence using circular dichroism. The spectral patterns 
of the compounds tended to fall into several main categories. To try to establish an 
interpretation of these patterns of CD signals, SPR studies were conducted on several 
compounds from each category. An example of each type of spectral pattern is shown 
along with its equilibrium binding constant for the strong, first binding site (if applicable) 
in Figures 2.20 through 2.28. 
 A number of compounds such as DB 860 (Figure 2.20) showed no change in CD 
signal when the compound was titrated into the DNA. As expected, these compounds 
typically did not show any binding as measured by surface plasmon resonance. 
 Several of the compounds, including DB 185 (Figure 2.21), showed increases in 
CD signal across all wavelengths, with no isoelliptic points. These compounds generally 
had very high SPR signals, but binding to the control flow cell was equal to or larger than 
binding to the cell containing DNA. This behavior is consistent with non-specific 
aggregation of the compound onto the DNA, and not actual binding. 
 Upon titration, several compounds caused a decrease in the CD signal of the DNA 
at 260 nm. A negative peak at 260 nm has been associated with formation of a basket or 
chair-type antiparallel quadruplex conformation [46]. One example, DB 1065 (Figure 
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2.22) has K1 = 4.4 x 105 M-1. The CD spectra of DB 634 (Figure 2.23) also show a 
decrease at 260 nm when it was titrated into the DNA. However, the 295 nm peak 
increases during the titration. The K1 for this compound with human telomere is 2.3 x 105 
M-1, which is lower than the binding constant for DB 1065. In general, changes in CD 
signal at 295 nm do not seem to have a significant effect on the binding constant. It has 
been suggested that changes in signal at this wavelength are caused by conformational 
changes in the loops. Since these compounds likely are binding on the quadruplex ends or 
in the grooves, it is likely that the binding constant would be unaffected by 
conformational changes in the loops. 
 The spectra of compounds such as DB 587 (Figure 2.24) show the formation of a 
peak around 270 nm as the titration proceeds. This spectral pattern is associated with the 
formation of a parallel quadruplex structure [46]. For this compound, since the peak at 
295 does not change, it suggests that the compound is inducing or trapping out a mixed 
parallel/antiparallel hybrid quadruplex structure. K1 for this compound is 9.7 x 104 M-1. 
Compounds that exhibited induced CD signals generally had the highest binding 
constants among those screened. Two examples of compounds that exhibit a positive 
induced CD signal when titrated into the human telomeric DNA are DB 989 (Figure 
2.25) and DB 210 (Figure 2.26). Based on established pattern recognition for DNA, DB 
989 appears to be binding to an antiparallel conformation of DNA and DB 210 appears to 
bind to a mixed parallel/antiparallel hybrid conformation. K1 for DB 989 is 5.1 x 106 M-1. 
K1 for DB 210 is 1.6 x 106 M-1. In studies with duplex DNA, a positive induced signal is 
usually indicative of groove binding [47]. It is likely that these compounds are binding in 
the grooves of the human telomere as monomers. This library of compounds was 
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designed as potential DNA groove binders. They generally have the crescent-type shape 
that has been shown to fit into the grooves of DNA. The compounds do not have the 
large, planar, aromatic surfaces required for extensive π- π stacking with quadruplex 
ends. It is likely that any strong binding compounds are therefore binding in the 
quadruplex grooves. 
DB 1300 (Figure 2.27)  and several compounds with similar structures bind to the 
human telomere with strong induced exciton CD signals, suggesting binding as a stacked 
complex or complexes. K1 for this compound with the human telomere is 2.7 x 106 M-1. 
The CD signal in the DNA region shows a dramatic decrease as the titration progresses. 
The resulting spectrum for the DNA does not follow any established CD pattern for the 
conformation of quadruplex DNA. Although this group of compounds appear to bind to 
the telomere as stacked species with a fairly high level of affinity, this group of 
compounds was not chosen for further study, due to the difficulty in analyzing the DNA 
conformation.  
A bifuryl compound, DB832, also exhibited strong induced exciton CD signals 
when titrated into telomeric DNA (Figure 2.28). The large magnitude of the signal 
suggests that it probably forms stacked complexes in more than one groove. Due to the 
high stoichiometry of the system, a reliable binding constant was not able to be measured 
using surface plasmon resonance. Addition of this compound results in a CD pattern for 
the DNA region that is indicative of formation of a mixed parallel/antiparallel hybrid 
structure. Since this appears to bind in the quadruplex grooves as a stacked species, and 
interacts with the DNA in a well-defined manner, it was chosen for further study as 
presented in Chapters 3 and 4. 
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Conclusion 
Since the grooves of quadruplex DNA structures have different geometries than 
with duplex DNAs as well as different patterns of donor-acceptor, hydrogen-bonding 
sites [20, 48], compounds that bind only in the grooves should be able to achieve 
excellent structure-specific recognition affinity and specificity. CD results for a cyanine 
dye, DODC, established that the grooves of telomeric DNA can be targeted by small 
molecules as stacked species.  
Based on these results, a library of heterocyclic diamidine dications was 
investigated using CD spectroscopy. The screening process yielded a variety of CD 
patterns, both in the induced region as well as the DNA region. CD patterns in the DNA 
region show that different conformations of the human telomere including antiparallel 
and mixed parallel/antiparallel hybrids can be selectively targeted by small molecules. 
Patterns in the induced region suggest that a positive induced CD is indicative of binding 
in the grooves as a monomer, and an induced exciton signal indicates binding in the 
grooves as one or more stacked species. Binding as a stacked species is of particular 
interest since studies with duplex DNA have shown that stacked species can have 
improved binding affinity and selectivity over monomer binding. 
Through the screening process, a heterocyclic diamidine molecule, DB 832, was 
identified as a possible quadruplex groove binder. This compound exhibited the 
characteristic strong exciton induced CD signals associated with groove binding. The 
large magnitude of the signals suggests that it may bind as a series of stacked species. 
This compound may serve as the starting point for the design of a new class of highly 
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selective quadruplex DNA groove binders and is the subject of further investigation in 
Chapters 3 and 4.  
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Figure 2.1 CD spectra of ethidium bromide titrated into 3.0 µM of d[AG3(T2AG3)3] in 
HEPES buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
 
  41   
-2
0
2
4
6
8
10
12
250 300 350 400 450
DNA-buffer
.5:1-buffer
1:1-buffer
1.5:1-buffer
2:1-buffer
2.5:1-buffer
3:1-buffer
3.5:1-buffer
C
D
 (m
de
g)
wavelength (nm)
 
N
O
H
N
N
O
H
N
N
O
H
N
H2N NH2
H
N
H
O
CH3
CH3
CH3 +
 
 
Figure 2.2 CD spectra of distamycin A titrated into 3.0 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 3.5:1. 
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Figure 2.3 CD spectra of neomycin  titrated into 3.8 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 4:1. 
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Figure 2.4 CD spectra of fImImIm titrated into 2.9 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 2.5 CD spectra of thionin titrated into 3.0 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 4:1. 
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Figure 2.6 CD spectra of chromomycin A3 titrated into 3.9 µM of d[AG3(T2AG3)3] in 
HEPES buffer containing 50 mM KCl and 50 mM MgCl2. Compound:DNA ratios ranged 
from 1:1 to 6:1. 
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Figure 2.7 CD spectra of chromomycin A3 titrated into 2.9 µM of d[AG3TG4AG3TG4A] 
in HEPES buffer containing 50 mM KCl and 50 mM MgCl2. Compound:DNA ratios 
ranged from 1:1 to 5:1. 
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Figure 2.8 CD spectra of mithramycin titrated into 4.5 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl and 50 mM MgCl2. Compound:DNA ratios ranged from 
1:1 to 7:1. 
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Figure 2.9 CD spectra of mithramycin titrated into 1.7 µM of d[AG3TG4AG3TG4A] in 
HEPES buffer containing 50 mM KCl and 50 mM MgCl2. Compound:DNA ratios ranged 
from 1:1 to 6:1. 
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Figure 2.10 CD spectra of mithramycin titrated into 4.1 µM of d[AG3(T2AG3)3] in 
HEPES buffer containing 50 mM NaCl and 50 mM MgCl2. Compound:DNA ratios 
ranged from 1:1 to 7:1. 
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Figure 2.11 CD spectra of mithramycin titrated into 4.0 µM of d[AG3(T2AG3)3] in 
HEPES buffer containing 50 mM LiCl and 50 mM MgCl2. Compound:DNA ratios 
ranged from 1:1 to 6:1. 
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Figure 2.12 CD spectrum of 31.7 mM mithramycin added to 4.5 µM of d[AG3(T2AG3)3] 
minus the CD spectrum of 31.7 mM mithramycin alone. Both samples were prepared in 
HEPES buffer containing 50 mM KCl and 50 mM MgCl2. 
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Figure 2.13 CD spectra of 31.7 mM mithramycin in HEPES buffer containing 50 mM 
KCl and 50 mM MgCl2 at zero and one hour. 
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Figure 2.14 Sensorgrams for mithramycin binding to the human telomere, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM K+ and 10 mM Mg2+. The 
concentration ranges from 0.0 µM to 2.0 µM. 
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Figure 2.15 CD spectra of diethyloxadicarbocyanine (DODC)  titrated into 3.1 µM of 
d[AG3(T2AG3)3] in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 0.5:1 to 5.5:1. 
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Figure 2.16 CD spectra of (DOC) titrated into 2.8 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 0.5:1 to 3.5:1. 
 
 
  56   
-4
-2
0
2
4
6
8
10
300 400 500 600 700
DNA -buffer
0.5:1-buffer
1:1-buffer
1.5:1-buffer
2:1-buffer
2.5:1-buffer
3:1-buffer
3.5:1-buffer
4:1-buffer
C
D
 (m
de
g)
wavelength (nm)
 
 
S
N N
S
+
 
 
 
Figure 2.17 CD spectra of (DTDC) titrated into 3.2 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 0.5:1 to 4:1. 
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Figure 2.18 CD spectra of (DTC)  titrated into 3.2 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 0.5:1 to 5.5:1. 
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Figure 2.19 Direct binding plot for DODC to the human telomere, d[AG3(T2AG3)3], in 
HEPES buffer containing 200 mM K+ fitted to a two-site model. The concentration axis 
is for unbound DODC concentration in the flow solution.  
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Figure 2.20 CD spectra of DB 860 titrated into 3.8 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 4:1. 
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Figure 2.21 CD spectra of DB 185 titrated into 3.6 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 3:1. 
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Figure 2.22 CD spectra of DB 1065 titrated into 3.4 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 4:1. 
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Figure 2.23 CD spectra of DB 634 titrated into 4.1 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 4:1. 
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Figure 2.24 CD spectra of DB 587 titrated into 3.9 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 2.25 CD spectra of DB 989 titrated into 3.7 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 2.26 CD spectra of DB 210 titrated into 3.3 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
K1 = 1.6 x 106 M-1 
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Figure 2.27 CD spectra of DB 1300 titrated into 4.2 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 6:1. 
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Figure 2.28 CD spectra of DB 832 titrated into 3.0 µM of d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 0.5:1 to 5:1. 
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Chapter 3 
Evaluation of a Heterocyclic Diamidine that Binds to the Grooves 
of Quadruplex DNA as a Stacked Species                                                    
Introduction 
Discovery and design of compounds that target G-quadruplex structures in DNA 
is a relatively new area that is now being rapidly driven by the desire to discover new 
anti-cancer drugs and targets. Many small molecules known to bind quadruplex DNA are 
planar, aromatic compounds that are based on or derived from or are quite similar to 
duplex intercalators. These molecules generally bind to the quadruplex via end-stacking 
on either or both of the terminal G-tetrads. Because of the structural similarity to 
intercalators, many of these quadruplex-binding molecules exhibit limited selectivity for 
quadruplex over duplex structures. Binding to non-targeted duplex sequences can result 
in significant loss of compound with potential nonselective cytotoxicity. Since potential 
quadruplex-forming sequences are common in the genome, selectivity for a particular 
quadruplex structure over other quadruplexes is also a concern in the design of 
quadruplex-binding compounds. Binding to non-targeted quadruplex sequences results in 
compound loss and may have unintentional effects on regulation of non-targeted genes. 
Increasing selectivity of telomerase inhibitors for their targets is therefore an important 
focus of research.  
 Other modes of binding, including intercalation between tetrads as well as 
groove-binding have been proposed. Ethidium bromide has been proposed to intercalate
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 between tetrads, although structural evidence to support this claim is lacking [1]. G-
quadruplex intercalation is not considered to be a generally viable binding mode due to 
its high energetic cost and similarity to duplex intercalation [2]. Shafer et al. have 
investigated the interaction of the carbocyanine dye 3,3’-diethyloxadicarbocyanine 
(DODC) with a dimeric hairpin G-quadruplex [3]. Spectroscopic data suggests that this 
molecule binds in one or more of the quadruplex grooves. Satellite hole spectroscopy 
studies by Chang et al. support the groove-binding model for this particular ligand/DNA 
pair [4, 5]. Kerwin and coworkers have used electrospray mass spectrometry to 
investigate the interaction of the carbocyanine dye DTC with a different four-stranded 
intermolecular quadruplex [6]. The fragmentation pattern upon ionization suggests that 
this molecule binds in the grooves of this quadruplex as well. Randazzo et al. have 
investigated the interaction of distamycin with a four-stranded intermolecular quadruplex 
[7]. Their NMR results suggest that distamycin binds in one quadruplex groove as a 
dimer, but is capable of binding to two grooves at higher concentrations. However, 
Maizels and coworkers have shown with NMR that distamycin binds via an end-stacking 
mechanism to several four-stranded intermolecular quadruplexes, including one formed 
from the human telomeric sequence [8]. Thus, although G-quadruplex end-stacking is a 
well-established and documented recognition mode, binding in the G-quadruplex grooves 
is an area that lacks adequate models for drug design and development.  
 Quadruplex groove-binding may offer an attractive strategy for exploiting the 
structural differences between duplex and quadruplex DNA, leading to possible increased 
selectivity of recognition over traditional planar end-stacking molecules. Since groove 
dimensions vary significantly according to the type of quadruplex, groove-binding also 
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offers the opportunity for obtaining increased selectivity for a particular quadruplex 
structure. The geometry of the G-quartet is not greatly affected by the glycosidic 
(syn/anti) conformation or the strand orientation of the quadruplex [9]. However, groove 
dimensions are strongly dependent on these factors, resulting in a wide variety of possible 
groove geometries. The groove structural variation allows for the targeting of certain 
quadruplex sequences with a high degree of selectivity. In spite of extensive experiments 
on telomeres, no compounds to date have been found which bind to the grooves of the 
human telomere sequence. A library of diamidines synthesized by Boykin and coworkers 
at Georgia State University was screened against the human telomeric sequence using 
circular dichroism as described in Chapter 2. DB 832 was identified as a potential stacked 
quadruplex groove-binder and selected for further study. In this chapter, we use several 
biochemical methods to show that the heterocyclic diamidine DB 832 binds selectively as 
a stacked species with high (yet discrete) stoichiometry to a mixed parallel/antiparallel 
hybrid quadruplex structure. This molecule serves as a paradigm to show that the grooves 
of the human telomere can indeed be targeted and it can also serve as the starting point 
for the design of new molecules that may have therapeutic use as anti-cancer or anti-
trypanosomal agents. 
Materials and Methods 
Sample Preparation 
The oligonucleotides d[AG3(T2AG3)3], d(AG3TG4AG3TG4A), 
d(GCGAATTCGC), d(TAGGGUTAGGGT), and d(TAGGGUUAGGGT) were 
purchased with HPLC purification from Midland Certified Reagent Company. The 
oligonucleotide d(ABrGGTTABrGGTTAGGGTTABrGG) was purchased with HPLC 
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purification from IDT. The oligonucleotides 
d(TAATACGACTCACTATAGCAATTGCGTG), and 
d[TCCAACTATGTATAC(TTAGGG)4TTAGCGGCACGCAATTGCTATAGTGAGTC
GTATTA], were purchased from  Biosearch Technologies. The G-quadruplex DNA 
samples were dissolved in buffer to the desired concentrations, heated to 85 0C and 
cooled slowly to insure the folding of the quadruplexes prior to each experiment. The 
concentration of each DNA sample was determined spectrophotometrically at 260 nm 
using the nearest neighbor extinction coefficient at 80°C and extrapolated to 20°C. 
pUC19 plasmid DNA was purchased from Sigma. Stock solutions containing 1 mM each 
of DB 832 and Se2SAP were prepared in double distilled water and diluted to working 
concentrations immediately before use with buffer. The synthesis of DB 832 will be 
described elsewhere. The synthesis of Se2SAP has been previously described [10]. 
Absorbance and CD Measurements 
Absorbance and CD measurements were performed at 20°C in a 10 mM HEPES 
buffer (pH 7.4) containing 3 mM EDTA and 50 mM KCl or NaCl. For CD measurements 
obtained in the presence of 50 mM LiCl or in the absence of added salt, a 10 mM TRIS 
buffer containing 3 mM EDTA acid and pH adjusted to 7.4 using TRIS was used. CD 
spectra were recorded using a Jasco J-810 spectrapolarimeter in a 1-cm cell using an 
instrument scanning speed of 50 nm/min with a response time of 1 s. The spectra were 
averaged over four scans. Absorbance spectra were obtained on a Cary Varian 300 BIO 
UV-visible spectrophotometer in a quartz cell with a 1 cm pathlength. Appropriate 
amounts of stock solution of DB 832 or DNA were added sequentially to increase the 
molar ratio. A buffer baseline scan was collected in the same cuvette and subtracted from 
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the average scan for each absorbance and CD experiment. In the case of reverse 
absorbance titration, a second cuvette containing buffer was titrated with DB 832 in the 
absence of DNA. The absorbance spectrum of the free DB 832 was subtracted from the 
spectrum of the DB 832-DNA complex at each concentration. Data manipulation and 
plotting was performed using the program Kaleidagraph version 3.6. 
Isothermal Titration Calorimetry 
ITC experiments were performed with a MicroCal VP-ITC (MicroCal Inc., 
Northampton, MA, USA). HEPES buffer containing 10 mM HEPES, 3 mM EDTA, and 
50 mM KCl and pH adjusted to 7.4 was used for the ITC experiments. The compound 
was injected into the DNA in the sample cell in 5 µL increments. The observed heat for 
each injection was determined by integration of the injection peak areas with respect with 
time. Blank titrations were conducted by injecting the compound into the sample cell 
containing only buffer under the same conditions. The corrected interaction heat was 
determined by subtracting the blank heat from that for the compound/DNA titration. 
Number of binding sites was determined by fitting with Origin. 
Nuclear Magnetic Resonance Studies  
DNA samples were prepared in phosphate buffer containing 50 mM KCl, 10 mM 
K2HPO4, 0.1 mM EDTA and 0.01 mM DSS as an internal reference. Quadruplex DNA 
concentration for the U6 and U6U7 sequences were 0.1mM for 1D experiments and 
0.5mM for 2D experiments in 90% H2O:10% D2O (Cambridge Isotope Laboratories, 
Inc.) The final DNA samples were adjusted to pH 7.0 using 1M HCl or 1M KOH 
solutions and were heated past their transition temperature and annealed to room 
temperature for several hours before collecting the spectra.  Experiments on U6 and 
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U6U7 sequences were performed on Bruker AMX-600 and Varian Unity600 
spectrometers respectively. DB832 was titrated with quadruplex DNA with DB832:DNA 
ratios varying from 0.5 to 2. Temperature dependent 1D spectra were recorded from 15ºC 
to 50ºC using jump-return [11] and WATERGATE [12] methods for solvent suppression; 
whereas homonuclear TOCSY [13, 14] on U6U7 was performed at 35ºC using  
WATERGATE solvent suppression method with a mixing time of 60ms. All NMR data 
were processed and analyzed with the programs XWINNMR (Bruker Instruments), 
VNMR (Varian Inc.) and SPARKY [15].  
Taq Polymerase Stop Assay 
The DNA primer P28 was 5’-end-labeled with [γ-32P] ATP according to 
manufacturer’s protocol (New England Biolabs, Ipswich, MA) and purified with a Bio-
Spin 6 chromatography column (Bio-Rad, Hercules, CA) to remove free γ-32P. The 5’-
end-labeled primer P28 (100 nM) and the human telomeric template DNA (100 nM) were 
annealed in the annealing buffer (50µM Tris-HCl, 10µM NaCl, pH7.5) by heating at 
95°C and slowly cooling down to room temperature. The primer-annealed DNA template 
was purified using electrophoresis on a 12% native polyacrylamide gel. The purified 
primer-template DNA was counted and 5000 counts/min of DNA was used in a primer 
extension assay. In the primer extension assay, 5000 counts/min of DNA was mixed with 
2µl of 10x reaction buffer (provided with the Klenow fragment, Hanover, MD), 1µl of 
10mM dNTP, 2µl of 1M KCl (to a final concentration of 100mM in 20µl total volume) 
and different concentrations of compounds (DB 832 and Se2SAP). The reaction mixtures 
were incubated at room temperature for 30 min, and then Klenow fragment was added to 
each sample. All samples were incubated at 37°C for 30min, and were stopped by adding 
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same volume of stop buffer (10mM EDTA, 0.1% xylene cyanole, 0.1% bromophenol 
blue in formamide solution). The samples were resolved on a 16% denaturing 
polyacrylamide gel. 
pUC19 Photocleavage  
Individual reactions contained 38 µM bp pUC19 plasmid DNA in the presence or 
absence of 10µM DB 832. The buffer concentration for each reaction was 20 mM in a 
total volume of 20 µL. Reactions were kept in the dark or were irradiated at 419 nm for 
50 min at 22 °C in 1.7 mL microcentrifuge tubes with eight fluorescent lamps located 6 
cm above the opened tubes. Aerobic ventilation was achieved by placing a table fan 
directly adjacent to the lamps. Half the samples were treated with 0.3% piperdine at 65°C 
for 30 minutes, and half left untreated as a control. Cleavage products were 
electrophoresed on a 1.0% nondenaturing agarose gel stained with ethidium bromide (0.5 
µg/mL). The gel was then visualized on a transilluminator set at 302 nm, photographed, 
and scanned.  
Quadruplex Photocleavage  
The DNA was 5’-labeled with 32P and stored in buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0) at 3000 cpm/µl. For each photocleavage reaction, 10 µl of DNA (~5 ng) 
was mixed with 10 µl of 100 mM KCl, boiled for 10 minutes and cooled to room 
temperature. The DNAs used were a 74-mer human telomeric sequence, and a 77-mer c-
MYC G-quadruplex sequence. For the control experiments, 10 µl of distilled water was 
added instead of the KCl solution. The mixtures were transferred to a 96 well plate and 
varying amounts of DB 832 or telomestatin stock solution were added. The samples were 
then exposed to a 24 W fluorescent lamp under a glass filter. The reactions were stopped 
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with 100 µl of calf thymus DNA (0.1 µg/µl) and after phenol-choloroform extraction, the 
samples were subjected to piperdine to induce strand breakage and then precipitated with 
ethanol. The DNA samples were separated using electrophoresis on a 12% 
polyacrylamide gel and visualized using a phosphorimager. 
Fluorescence Measurements 
A Fluorescence energy transfer experiment was performed using a Cary Eclipse 
fluorescence spectrometer. All measurements were conducted at 20°C in a 10 mM 
HEPES buffer (pH 7.4) containing 3 mM EDTA and 50 mM KCl. A quartz cell with a 
1.0 cm pathlength was used. The emission wavelength was set to 469 nm with an 
excitation slit width of 5 nm. The excitation spectrum was scanned from 230 to 330 nm 
for DB 832 alone and in the presence of d[AG3(T2AG3)3]. The DB 832 concentration was 
0.3 µM and the DNA concentration was 8 µM. 
TRAP Assay  
A TRAP (Telomeric Repeat Amplification Protocol) assay was performed using a 
TRAPese Telomerase Dectection Kit S7700 (Chemicon International). The resulting 
products were run on a 12% non-denaturing polyacrylamide gel in 0.5x TBE buffer and 
visualized with a phosphorimager.  
Results and Discussion 
DB 832 Binds to the Human Telomere as a Stacked Species 
Achiral molecules, such as DB 832, exhibit no CD signal in solution. However, 
when an achiral ligand binds tightly to a chiral host, such as DNA, a CD signal is 
generally induced in the wavelength region corresponding to the absorbance of the ligand 
[16]. Figure 3.1 shows the CD spectra of the human telomeric sequence titrated with DB 
  82   
832 in the presence of K+. The spectra show an induced CD signal, which indicates that 
DB 832 is binding to the DNA. As compound is added to DNA the induced signal 
exhibits exciton-type splitting with a positive band centered at 432 nm, a negative band 
centered at 416 nm, and an isoelliptic point at 424 nm, which is also the absorbance 
maximum of the dye when bound to DNA. An additional negative band centered at 395 
nm overlaps with the higher energy exciton band. The exciton band indicates that DB 832 
is binding to the DNA as a stacked species, likely located in a quadruplex groove.  
The addition of DB 832 to the human telomeric DNA model sequence also affects 
the CD signal in the wavelength region of DNA absorbance (Figure 3.2). The 
interpretation of CD spectra is based heavily on pattern recognition. Many parallel-type 
quadruplexes, for example, have a characteristic strong positive CD band at 264 nm and a 
negative band at 240 nm, whereas antiparallel quadruplexes usually have a positive band 
between 290 and 295 nm and a negative band at 260-265 nm [17]. Upon addition of DB 
832, a peak appears around 265 nm, which is characteristic of parallel quadruplexes. The 
presence of a residual peak at 295 nm suggests the presence of an antiparallel structure. 
This data suggests that DB 832 either induces the formation of a mixed 
parallel/antiparallel hybrid quadruplex, or binds to a mixture of quadruplex 
conformations.  
An absorbance titration was performed to monitor changes in the spectral 
properties of DB 832 when bound to human telomeric DNA (Figure 3.3). Prior to 
addition of the DNA, the absorbance peak of the DB 832 monomer appears at 370 nm. 
As the DNA is added, this monomer peak decreases in intensity and a new peak is 
formed at around 425 nm, corresponding to the formation of the stacked species. This 
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bathochromic shift is indicative of the formation of a J-aggregate. In a J-aggregate, the 
transition dipole moments of the two chromophores within a dimer are oriented with a 
translational offset. Electronic transitions to the lowest exciton state are allowed, 
resulting in the red shift of the absorbance maximum [18, 19]. In the case of DB 832, the 
offset of this dimer structure allows the terminal positively-charged amidines to have a 
larger distance between the amidines on the adjacent molecule decreasing the electronic 
repulsion that would exist in an H-aggregate (non-offset) structure. The titration spectra 
also reveal an isosbestic point at 395 nm, indicative of a two-state transition. This 
suggests that the DB 832 is binding to the DNA with a discrete binding mode. 
An absorbance titration in which compound is titrated into the DNA was 
performed in order to further characterize the spectral properties of DB 832 upon binding 
to the telomeric DNA (Figure 3.4). Since the absorbance of free DB 832 is subtracted 
from the absorbance of the DB 832-DNA complex, the resulting signal can be positive or 
negative. The reverse titration also confirms that DB 832 binds to the human telomere 
with a discrete binding mode. 
In order to determine if DB 832 stacks in solution, or whether the stacking is 
DNA-mediated, the extinction coefficient of DB 832 was calculated in both buffer as 
well as ethanol (Figure 3.5) by calculating the slope of the absorbance versus 
concentration for each plot. The molar extinction of DB 832 was found to be 4.7 x 104 M-
1cm-1 in buffer and 5.9 x 104 M-1cm-1 in ethanol at 371 nm. In both cases, the extinction 
curve was linear over a wide concentration range, suggesting that no aggregation is 
occurring in solution as the concentration is increased. The difference between the two 
extinction coefficients is also not significant enough relative to experimental error to 
  84   
suggest that the DB 832 molecules are aggregating in solution. DODC is a well-studied 
cyanine dye that has been previously shown to stack in solution [20, 21]. The observed 
extinction coefficient for DODC monitored at 582 nm is 2.7 x 105 M-1cm-1 in ethanol and 
5.7 x 104 M-1cm-1 in buffer, illustrating the dramatic effect that stacking in solution can 
have on the extinction coefficient. The absence of observed DB 832 stacking in solution 
is supported by the fact that the molecule is dicationic, and therefore unlikely to stack in 
solution in the absence of a template due to repulsion from the positively charged 
amidine groups. The single charge on each DODC molecule is delocalized, and thus 
electrostatic repulsion between the molecules is much smaller than with DB 832. 
DB 832 Binds to the Human Telomere Cooperatively with High Stoichiometry 
Titration curves can be obtained from the spectroscopic titration data by plotting 
signal as a function of compound concentration for a given wavelength. Figures 3.6 and 
3.7 show titration curves for DB 832 with the human telomeric sequence 
d[AG3(T2AG3)3] using data obtained from the circular dichroism titration and the 
absorbance titration with DB 832 titrated into the DNA, respectively. Due to the high 
stoichiometry of the system, it is difficult to mathematically fit the data in order to obtain 
the exact stoichiometry or binding constants. However, a rudimentary fit of both curves 
reveals that there are approximately 12 molecules of DB 832 bound per quadruplex 
strand. Both curves are sigmoidal in shape, indicating that the binding of the DB 832 
molecules to this DNA sequence occurs with positive cooperativity, or two modes of 
binding. However, the absorbance titration data suggests that there is only one mode of 
binding, so it is likely that the binding of the DB 832 molecules is positively cooperative. 
A titration curve was also obtained for DB 832 using isothermal titration calorimetry. 
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Interaction heats for the titration of DB 832 into a DNA solution are shown in Figure 3.8. 
Plots of the observed net binding heat/mol versus molar ratio were obtained by 
subtracting the integrated peak areas for the blank titration from the areas in the DNA 
interaction titration. Due to the high stoichiometry, it was difficult to obtain a precise 
quantitative fit to the data using the Origin software. The best fit to the data arose from 
using a stoichiometry of n=10. This is in agreement with the high stoichiometry obtained 
from the CD and absorbance binding plots.  
The high stoichiometry suggests that DB 832 may actually be binding as a trimer, 
rather than a dimer. Since each quadruplex contains four grooves, one trimer located in 
each groove would produce a stoichiometry of 12, in agreement with our experimental 
results. A distinct break point occurs in all three binding curves at n=4. In the case of the 
CD titration spectra, no exciton splitting occurs until after four equivalents are present. 
Experiments by Armitage and coworkers have shown that for some cyanine compounds, 
exciton splitting does not occur between monomers within a single dimer, but is due to 
end-to-end interactions between the molecules [22, 23]. The exciton splitting that arises 
from end-to-end interactions has also been shown to produce CD signals of large 
magnitude [22] , in agreement with the large signals obtained for DB 832. This further 
suggests that DB 832 may be binding as a series of trimers. 
Some compounds, such as porphyrins, can aggregate onto the surface of 
quadruplex DNA, resulting in artificially high observed stoichiometries. The fact that 
each of the DB 832 binding curves distinctly levels off suggests that the high 
stoichiometry is not due to non-specific surface interactions. The isosbestic points 
observed in the absorbance titration and reverse absorbance titration further suggest that 
  86   
the binding of DB 832 to the telomeric DNA is indeed a discrete binding mode, and not 
surface aggregation.  
Effect of Salt on DB 832 Binding 
The CD spectrum for the human telomeric sequence has previously been shown to 
differ in the presence of sodium ions versus potassium ions [24]. This suggests that this 
DNA sequence exhibits a different conformation in the presence of each of these 
counterions. Differing NMR and crystal structures which were obtained in the presence 
of sodium ions and potassium ions, respectively, support this idea. The NMR structure of 
d[AG3(T2AG3)3] in the presence of potassium ions is an antiparallel basket-like structure 
[25]. The crystal structure of this sequence obtained in the presence of sodium ions 
consists of a parallel, propeller-like structure [26]. Other structures have been proposed to 
exist in solution in the presence of potassium, including a mixed parallel/antiparallel 
hybrid [27-30]. Lithium has been shown to have a destabilizing effect on quadruplex 
structure [31]. To investigate the effect of DNA structure on the binding of DB 832, CD 
titrations were performed with human telomeric DNA under different salt conditions to 
determine if DB 832 would bind as a stacked species to different conformations of this 
DNA sequence. Figure 3.9 shows the CD spectra for d[AG3(T2AG3)3] titrated with DB 
832 in the presence of 50 mM sodium, and 50 mM lithium, respectively. Regardless of 
the cation present, upon addition of DB 832 exciton splitting occurs in the induced 
wavelength region of the CD spectra. Figure 3.10 shows the DNA region for the spectra 
in Figure 3.9. Peaks occur in the DNA region at 265 and 295 nm, in the presence of 
sodium or lithium, as is the case when potassium is present. This suggests that regardless 
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of the starting conformation of the DNA, DB 832 induces the formation of a specific 
conformation of DNA to form an optimum binding site for the DB 832 stacked species.  
It is generally believed that salt is required to facilitate the formation of 
quadruplex structures from G-rich DNA [32]. The cations act to neutralize charge 
repulsion between the four negatively charged DNA strands as well as stabilize the 
quartets by coordinating with the carbonyl oxygen atoms from the guanines. Only 
telomestatin has previously been shown to induce quadruplex formation in human 
telomeric DNA in the absence of added salt [30, 33]. Figure 3.11 shows the DNA region 
of the CD spectra of the human telomeric DNA titrated with DB 832 in the absence of 
added salt. Peaks appear around 265 and 295 nm, resulting in the same CD pattern that 
the DNA produces when titrated by DB 832 in the presence of K+, Na+ or Li+, suggesting 
that the compound induces the same quadruplex conformation that is formed in the 
presence of these cations. In addition to a change in the CD spectra in the DNA region, 
DB 832 produces an induced CD signal when titrated into the DNA in the absence of salt. 
This confirms that the compound is binding to the DNA. However, the absence of exciton 
splitting indicates that the compound is binding as a monomer and not a stacked species 
under these conditions. Since DB 832 is a dication, it is reasonable to assume that 
stacking of the compound is not energetically favorable in the absence of salt due to 
charge repulsion from the amidine groups. The absorbance titration of DB 832 into 
human telomeric DNA exhibits a different spectral pattern in the absence of salt (Figure 
3.12) than in the presence of salt, further suggesting a different binding mode.  
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DB 832 Induces the Formation of a Single Quadruplex Structure 
To determine whether DB 832 is inducing the formation of a mixed 
parallel/antiparallel hybrid quadruplex structure or binding to a mixture of DNA 
conformations, 1-D NMR studies were performed by Rupesh Nanjunda using a modified 
human telomeric sequence previously described by Patel et al [34]. The sequence, 
d(TAGGGUTAGGGT), has been shown to exist in solution as a mixture of both parallel 
(major species) and antiparallel (minor species) dimeric hairpin quadruplexes. This 
sequence is suitable as a model system for studying interactions with DB 832, since the 
CD spectra of DB 832 titrated into this DNA exhibits the same patterns in both the 
induced wavelength region as well as the DNA region as with the intramolecular 
sequence d[AG3(T2AG3)3] (Figure 3.13). The imino proton spectra of DB 832 titrated 
into d(TAGGGUTAGGGT) are shown in Figure 3.14. As the molar ratio of DB 832 is 
increased, the NMR peaks become fewer and sharper, suggesting that the compound is 
binding to a single DNA conformation, and not a mixture of species. Another substitution 
was made to the U6 sequence at T7 position (T7-->U7) to determine if DB832 has 
similar effects on this sequence. CD and NMR results have shown that this sequence, 
d(TAGGGUUAGGGT), also exists as a mixture of both parallel and antiparallel dimeric 
hairpin quadruplex in solution (Figure 3.13).  The CD and imino region spectra of U6U7 
with DB832 exhibited similar patterns as in U6 sequence suggesting that DB832 is 
selectively binding to a single conformation from a mixture of species (Figure 3.14). This 
is further supported by the TOCSY spectra of uracil region of free U6U7 sequence and 
with DB832 at 2:1 ratio (Figure 3.15). The four peaks correspond to the two uracil 
protons from the mixture of parallel and antiparallel conformation. In the absence of 
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DB832, all the peaks are of similar intensity indicating the heterogeneity of the sequence. 
After titrating with DB832, there is a significant decrease in the intensity of peaks at 7.70 
and 7.52 ppm indicating that the compound is favorably binding to a particular 
conformation from the mixture.  
DB 832 Binds to the Same Human Telomere Hybrid Quadruplex as Se2SAP 
Diseleno Sapphyrin (Se2SAP) is a modified porphyrin compound which has been 
previously shown to bind via end-stacking to a mixed parallel/antiparallel hybrid 
conformation of intramolecular human telomeric quadruplex DNA [30]. To determine 
whether DB 832 and Se2SAP bind to the same quadruplex conformation of the human 
telomere, a Taq polymerase stop assay was performed by Laurence Hurley’s group at the 
University of Arizona. In a polymerase stop assay, G-quadruplex structures block primer 
extension by DNA polymerase, resulting in shortened DNA fragments known as stop 
products. The presence of stop products as determined by gel electrophoresis indicates 
quadruplex stabilization by the compound. The assay was performed for human telomeric 
DNA with DB 832, Se2SAP, and DB 832 and Se2SAP in combination. The assay shows 
that DB 832 interacts with and stabilizes the G-quadruplex in the human telomeric 
sequence in a dose-dependent manner (Figure 3.16, lanes 7-11). Figure 3.17 shows the 
normalized fold increase in stop product versus compound concentration for this set of 
compounds. The graph shows that DB 832 and Se2SAP have an additive effect on 
quadruplex stabilization. This indicates that these two compounds are not competing for 
binding sites or competing to trap out or induce different quadruplex conformations. This 
suggests that DB 832 binds to the same hybrid quadruplex conformation as Se2SAP, 
which is consistent with the CD and NMR results which show that DB 832 induces the 
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formation of a single conformation, which has both parallel and antiparallel 
characteristics. Furthermore, the absence of any major stop products at the primer site 
indicates that DB 832 does not bind duplex DNA (the primer and template heterodimer) 
at concentrations even as high as 25 µM (data not shown) which supports the premise 
that DB 832 selectively binds to quadruplex DNA. A CD competition titration of DB 832 
titrated into human telomeric DNA in the presence of Se2SAP is shown in Figure 3.18. 
The large magnitude of exciton splitting confirms that DB 832 and Se2SAP are not in 
competition for conformation or binding site. 
DB 832 Binds in the Grooves of Telomeric Quadruplex DNA 
 
Photoactive molecules can catalyze the oxidation of DNA upon exposure to light, 
causing strand breakage in the vicinity of their binding sites. Photocleavage of DNA has 
been used as an assay to determine the location of binding sites for photoactive molecules 
such as porphyrins [35-39]. In order to determine if DB 832 is photoactive, and therefore 
suitable for study using photocleavage experiments, its photoactivity was first assessed 
using pUC19 plasmid DNA (Figure 3.19). When the supercoiled circular pUC19 DNA is 
cleaved by a photoactive molecule, it becomes linear and travels slower on an 
electrophoretic gel. In the presence of light and treatment with piperdine, DB 832 cleaves 
the DNA in a dose-dependent manner. By 50 µM, no DNA bands appear on the gel, 
suggesting that the DNA is completely degraded by that point. In the presence of light, 
but absence of piperdine treatment, DB 832 still cleaves the DNA, but to a lesser extent. 
The DNA band disappears by 100 µM DB 832 concentration. The experiments were also 
conducted in the absence of light, as a control, as shown in the right side of Figure 3.19.  
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Since the pUC19 experiment shows that DB 832 is highly photoactive, a 
photocleavage assay with quadruplex DNA was performed by the Hurley group at the 
University of Arizona (Figure 3.20). In the presence of KCl, DB 832 cleaves the human 
telomeric sequence in a dose-dependent manner specifically at each run of guanines, 
which suggests that DB 832 binds in the grooves of this quadruplex sequence. As a 
control, the experiment was also performed in the absence of salt. Since quadruplex DNA 
sequences generally require salt to fold, any cleavage in the absence of salt is normally 
attributed to free compound in solution. In the absence of salt, DB 832 exhibits the same 
cleavage pattern as in the presence of salt. However, since DB 832 is capable of inducing 
quadruplex formation in the absence of salt, it is probable that this cleavage is due to 
actual binding and not from free DB 832 in solution. This is supported by the 
photocleavage results when the c-MYC sequence is treated with DB 832. In the presence 
of salt, DB 832 only cleaves at specific guanines, instead of all guanines, suggesting that 
free DB 832 in solution does not indiscriminantly cleave all guanines. This cleavage 
pattern also suggests that DB 832 is likely binding to the c-MYC sequence through an 
end-stacking interaction. The CD spectra of DB 832 with c-MYC (to be presented in 
Chapter 4) indeed does not show any induced signal, supporting the photocleavage 
results that suggest that DB 832 does not bind in the grooves of c-MYC, and therefore 
must be end-stacking. The photocleavage of the DNA sequences was also monitored in 
the presence of telomestatin. In the presence of KCl and telomestatin, DB 832 does not 
appear to cleave the telomeric DNA, which indicates that it is not binding under these 
conditions. Telomestatin has been shown to bind very strongly to a basket quadruplex 
structure in the human telomeric sequence in the presence of potassium ions [40]. Since 
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DB 832 has been shown to bind to a mixed parallel/antiparallel structure and not the 
antiparallel basket-type structure, it is therefore expected that DB 832 would not bind 
under these conditions. However, in the absence of KCl, DB 832 does cleave the 
telomeric DNA at every guanine.  Like DB 832, telomestatin can also induce quadruplex 
formation in the absence of salt [30, 33]. Since telomestatin is an uncharged molecule, 
while DB 832 is a dication, it is likely in the absence of salt that DB 832 has a stronger 
binding affinity to the negatively charged DNA than telomestatin does because of the 
favorable electrostatic interactions that are shielded in the presence of salt. 
Fluorescence energy transfer between the bases of the quadruplex DNA and the 
bound compound can also be used to provide evidence of the binding site location. When 
a compound stacks on the quadruplex ends or intercalates between tetrads, energy 
transfer from the DNA bases to the bound compound can occur. The fluorescence energy 
transfer between bound DB 832 and the human telomeric DNA was assessed by setting 
the emission wavelength to 469 nm (the emission λmax for bound DB 832) and scanning 
the excitation spectrum of DB 832 in the presence and absence of DNA (Figure 3.21). In 
the case of intercalation or end-stacking, a peak would appear at 260 nm in the excitation 
spectrum due to the absorbance of the DNA, indicating that energy transfer is occurring. 
However, when DNA is added to DB 832, the fluorescence decreases across all 
wavelengths, and a peak at 260 nm does not appear. This suggests that the DB 832 
molecules are located in the quadruplex grooves, at an orientation which prevents energy 
transfer from the DNA. 
The oligonucleotide d(ABrGGTTABrGGTTAGGGTTABrGG) is a modified human 
telomeric sequence in which three of the guanines have been substituted with the 
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modified nucleobase 8-bromoguanine, which blocks the quadruplex grooves. Substitution 
with 8-bromoguanine also causes the glycosidic conformation of the sugar associated 
with that base to adopt the syn conformation [41].  By selectively modulating the 
glycosidic orientations within the DNA sequence, the overall fold of the quadruplex can 
be controlled. Sugyiama and coworkers recently showed that the modified 
d(ABrGGTTABrGGTTAGGGTTABrGG) folds in a mixed parallel/antiparallel hybrid 
conformation, which is likely the structure the unmodified human telomere adopts in 
solution in the presence of K+ [42]. NMR data from Yang and coworkers showed that a 
different modified human telomeric structure also forms this same hybrid quadruplex 
structure [43], further suggesting that this structure is the one adopted by the human 
telomere in potassium, and thus the one that DB 832 binds to as a stacked species. The 
CD spectra of DB 832 titrated into this sequence is shown in Figure 3.22. The spectra 
show a positive band centered at 371 nm, and a small negative band centered at 419 nm. 
These bands likely are not due to exciton splitting, but are rather two separate bands. 
When DB 832 binds to the quadruplex as a stacked species, the negative band is the 
higher energy band and the positive band is the lower energy band. The two peaks are 
shifted an equal number of nanometers from the crossover point, which is also the 
maximum wavelength of DB 832 when it is bound to the human telomere.  In the case of 
this modified DNA, the positive band is at higher energy and the negative band is at 
lower energy. If this were an exciton signal, it would suggest that the compound (and 
hence the DNA) was oriented with an opposite-handed helicity than when DB 832 is 
bound to the unmodified sequence. Since we know that both DNAs have the same 
structure, it makes exciton splitting in this case unlikely. The peak of the positive band 
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also occurs 21 nm from the apparent crossover point, while the negative peak is located 
27 nm from the crossover point. The small magnitude of these bands suggests that this 
difference is not due to overlapping bands. The crossover point for this sequence occurs 
at 392 nm, which is not the maximum absorbance wavelength of DB 832 bound as a 
stacked species to the human telomere. Also, DB 832 does not exhibit a wavelength shift 
with this DNA, which suggests it is not binding as a stacked species. Since DB 832 does 
not exhibit any exciton splitting with this hybrid quadruplex structure when the grooves 
are blocked, it provides evidence that the mode of binding of this compound to the human 
telomere is groove binding as a stacked species. 
DB 832 Inhibits Telomerase 
In order to assess the biological activity of DB 832, a TRAP (Telomerase Repeat 
Amplification Protocol) assay was performed by the Hurley group at the University of 
Arizona. The TRAP assay is a PCR-based assay that measures telomerase-mediated 
primer extension. In the first step of the reaction, telomerase adds telomeric repeats onto 
the 3’ end of a substrate oligonucleotide (TS). The extended products are then amplified 
with PCR using the TS and reverse (RP) primers. The gel from the TRAP assay is shown 
in Figure 3.23. The relative densities of the telomeric bands for each concentration of DB 
832 were expressed relative to the untreated control. The plot showing the concentration-
dependent inhibition of telomerase by DB 832 is shown in Figure 3.24. A fit of this plot 
reveals the IC50 (concentration required for 50% inhibition of the protein) to be 10.8 µM, 
showing that DB 832 is an effective telomerase inhibitor. In comparison, the 
carbocyanine dye, DODC, which was also shown to bind the grooves of the human 
telomere (Chapter 2), does not inhibit telomerase at concentrations less than 50 µM [6]. 
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Conclusions 
Many DNA-targeted anti-cancer drugs act by intercalating between base pairs of 
duplex DNA, which causes a disruption in transcription and replication and leads to cell 
death. These types of small molecules typically exhibit non-selective binding to many 
sites, leading to the cytotoxic side effects generally associated with chemotherapy. 
Antiparastic therapeutics in use today also have significant toxicity to the host and can 
also cause debilitating side-effects. Telomeres and some oncogenes have been shown to 
form quadruplex structures in vitro, and may serve as structure-specific targets for 
anticancer as well as antiparastic therapeutics. The unique structural features of 
quadruplexes offer a way to target DNA in a structure-specific manner, leading to 
increased selectivity for quadruplex over duplex DNA, as well as selectivity for a 
particular quadruplex structure over other quadruplexes.  
DB 832 is a heterocyclic diamidine that binds to human telomeric DNA as a 
stacked species. Regardless of the starting conformation of the human telomeric DNA, 
DB 832 is capable of inducing the formation of a mixed parallel/antiparallel hybrid 
quadruplex structure, and can even induce formation of this structure in the absence of 
salt. Nonintercalating, stacked species, such as DB 832, offer unique opportunities for 
drug design. The monomer units can potentially be covalently linked, resulting in 
extremely increased affinity and selectivity for their quadruplex targets. 
Photocleavage and fluorescence energy transfer experiments suggest that DB 832 
is a groove-binding agent in the human telomere. The compound does not have the large 
planar surface area of well-known end-stacking agents, such as anthraquinones, acridines, 
porphyrins, perelynes, macrocycles and related molecules. The fact that DB 832 binds to 
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the human telomere as a stacked complex also makes a groove complex more likely. 
There is little advantage to multiple stacking on the end of a quadruplex, but stacking in a 
groove can optimize the fit of cationic heterocycles to DNA. Stacked dimers that bind to 
duplex DNA grooves are quite well known and can yield exceptionally stable complexes. 
Structural studies are currently in progress to determine the exact orientation of DB 832 
molecules with respect to each other as well to the DNA. 
DB 832 may provide a starting point for the design of unique compounds with 
high affinity and selectivity for human telomeric DNA, leading to improved therapeutics 
for treating cancer and parasitic infections with decreased side effects.  
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Figure 3.1 CD spectra of DB 832 titrated into 3.0 µM d[AG3(T2AG3)3] in HEPES buffer 
containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 3.2 Close-up of the wavelength region of DNA absorbance for the spectra shown 
in Figure 3.1 of of DB 832 titrated into 3.0 µM d[AG3(T2AG3)3] in HEPES buffer 
containing 50 mM KCl. The arrow indicates increasing DB 832 concentration. 
Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 3.3 Absorbance spectra of d[AG3(T2AG3)3] titrated 8.2 µM DB 832 in a HEPES 
buffer containing 50 mM KCl, up to a final DNA concentration of 4.4 µM. 
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Figure 3.4 Absorbance spectra of DB 832 titrated into 3.8 µM d[AG3(T2AG3)3] in 
HEPES buffer containing 50 mM KCl up to a final DB 832/DNA ratio of 26:1. The 
arrows indicates increasing DB 832 concentration 
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Figure 3.5 Extinction coefficient determination for DB 832 in HEPES buffer containing 
50 mM KCl (top) and ethanol (bottom) monitored at 371 nm. 
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Figure 3.6 Titration curve for DB 832 obtained by plotting CD signal at 431 nm as a 
function of DB 832 added molar ratio. DB 832 was added to 3.5 µM d[AG3(T2AG3)3] up 
to a compound/DNA ratio of 24:1, in phosphate buffer containing 70 mM K+.  
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Figure 3.7 Titration curve for DB 832 obtained by plotting ∆A at 422 nm as a function of 
added DB 832 molar ratio. DB 832 was.titrated into 3.8 µM d[AG3(T2AG3)3] in HEPES 
buffer containing 50 mM KCl up to a final DB 832/DNA ratio of 26:1. 
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Figure 3.8 Isothermal titration calorimetry plot of DB 832 titrated into a 5 µM 
d[AG3(T2AG3)3] solution (top) in HEPES buffer containing 50 mM KCl. Plot of heat 
versus molar ratio (bottom) was obtained by subtracting the integrated peak areas for the 
blank, buffer titration from the DNA interaction titration.  
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Figure 3.9 CD spectra of DB 832 titrated into 3.0 µM d[AG3(T2AG3)3] in buffer 
containing 50 mM NaCl (top) and 50 mM LiCl (bottom). Compound:DNA ratios ranged 
from 1:1 to 5:1. 
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Figure 3.10 Close-up of the wavelength region of DNA absorbance for the spectra shown 
in Figure 3.9. The arrows indicate increasing DB 832 concentration. 
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Figure 3.11 CD spectra of DB 832 titrated into 3.9 µM d[AG3(T2AG3)3] in 10 mM TRIS 
buffer in the absence of added salt. Compound:DNA ratios ranged from 1:1 to 8:1. The 
arrow represents increasing DB 832 concentration. 
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Figure 3.12 Absorbance spectra of d[AG3(T2AG3)3] titrated 8.0 µM DB 832 in 10 mM 
TRIS buffer in the absence of added salt, up to a final DNA concentration of 1.1µM. The 
arrows indicates increasing DB 832 concentration 
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Figure 3.13 CD spectra of DB 832 titrated into 4.0 µM d[TAGGGUTAGGGT] hairpin 
dimer up to a compound/DNA ratio of 3:1 (top) and d[TAGGGUUAGGGT] (bottom) up 
to a compound/DNA ratio of 6:1 in phosphate buffer containing 70 mM K+.  
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Figure 3.14 NMR imino proton titrations of (A) d(TAGGGUTAGGGT) and (B) 
d(TAGGGUUAGGGT) dimeric hairpin quadruplexes with DB 832 at 308 K and (C) 
d[AG3(T2AG3)3] at 298 K in the presence of phosphate buffer containing 70 mM K+. 
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Figure 3.15 TOCSY spectra of uracil H5-H6 cross-peaks for 0.5 mM 
d[TAGGGUUAGGGT] at 0:1 and 2:1 DB 832 molar ratios. Spectra were obtained with a 
60 ms mixing time at 35°C in phosphate buffer containing 70 mM K+. 
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Figure 3.16 Concentration-dependent inhibition of Taq polymerase DNA synthesis by 
stabilization of the human telomeric G-quadruplex structure with Se2SAP (0-5µM), DB 
832 (0-5 µM), or both (0-5 µM), using a DNA template containing the telomeric 
sequence at 37ºC in 100 mM KCl. 
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Figure 3.17 Graphical representation of the quantification of the autoradiogram in Figure 
3.16 showing the normalized fold increase of stop product versus concentration. 
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Figure 3.18 CD spectra of DB 832 titrated into 2.3 µM d[AG3(T2AG3)3] containing 2.7 
µM Se2SAP in HEPES buffer with 50 mM KCl. DB 832:DNA ratios ranged from 0.5:1 
to 6:1. 
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Figure 3.19 Photocleavage of puC19 plasmid DNA by DB 832 in the presence and 
absence of piperdine. The samples in the left gel were illuminated for 50 minutes at 419 
nm. The samples on the right were left in the dark as a control. 
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Figure 3.20 Photocleavage of 74-mer human telomeric DNA and 77-mer c-MYC DNA 
sequences by DB 832, telomestatin, or DB 832 and telomestatin in the presence and 
absence of KCl.  
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Figure 3.21 DB 832 fluorescence excitation spectra of 0.3 µM DB 832 alone and in the 
presence of 8 µM d[AG3(T2AG3)3] in HEPES buffer containing 50 mM KCl. The 
emission wavelength was set at 469 nm. 
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Figure 3.22 CD spectra of DB 832 titrated into 2.1 µM 
d(ABrGGTTABrGGTTAGGGTTABrGG), in phosphate buffer containing 70 mM KCl. 
Compound:DNA ratios ranged from 2:1 to 20:1. 
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Figure 3.23 Gel showing TRAP assay extension products for DNA treated with different 
concentrations of DB 832. Lane 1 is a 1x cell lysis buffer control and lane 2 is the 
untreated TSR8 control template. 
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Figure 3.24 Plot showing telomerase inhibition by DB 832 relative to the untreated 
control as a function of concentration as determined from the TRAP assay. 
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Chapter 4 
Selectivity of Quadruplex Binding as a Stacked Species:  
Effect of DNA and Compound Structure 
Introduction 
G-quadruplex DNA differs from Watson-Crick duplex DNA in that the structures 
of quadruplexes are very sensitive to conditions and can be highly polymorphic. 
Quadruplex DNA can form different structures depending on sequence, length, 
concentration, nature of cations present, presence of crowding agents and other factors 
[1-5]. Shorter sequences can form intermolecular two-or four strand structures. Longer 
sequences can form intramolecular quadruplex structures including antiparallel basket 
and chair quadruplexes, parallel propeller quadruplexes, and mixed parallel/antiparallel 
hybrid structures [6-12]. Some intramolecular sequences can also form intermolecular 
quadruplex structures known as “G-wires” under certain conditions [13]. Some 
quadruplex-forming sequences can exist as a mixture of structures in solution, and even 
interconvert. The promoter region of the c-MYC oncogene has been shown to exist as 
mixture of four loop isomers [14]. The bcl-2 proto-oncogene has been shown to exist as a 
mixture of three different quadruplex structures [15, 16]. A two-repeat human telomeric 
sequence has been shown to form interconverting parallel and antiparallel G-
quadruplexes in solution [17]. Evidence suggests that the intramolecular human telomeric 
sequence may exist as a mixture of structures in the presence of potassium [17-19]. Some 
small molecules have been shown to induce a conformation change of quadruplex DNA 
upon binding [14, 20]. In the case of the purine-rich strand of the promoter region of the 
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c-MYC oncogene, it has been proposed that binding of a small molecule is not sufficient 
to modulate transcription; a conformation change in the quadruplex must occur for 
effective down-regulation of the gene [14]. 
The extensive variation among quadruplex structures, combined with the fact that 
some small molecules can induce or trap out a particular conformation may allow the 
design of compounds that can target particular quadruplex structures with a high degree 
of selectivity. Selectivity of a compound for quadruplex over duplex DNA is important 
because indiscriminant duplex-binding is associated with cytotoxicity and can also result 
in significant loss of compound. However, selectivity for a certain quadruplex structure 
over other non-targeted quadruplexes is also a very important consideration in design of 
quadruplex-interactive agents. Potential quadruplex-forming sequences are common in 
the genome. Telomeric DNA, immunoglobulin switch region sequences, the fragile X 
repeat sequence, promoter regions of some oncogenes, the insulin gene and other 
genomic sequences have been shown to form quadruplex structures in vitro [10, 11, 21-
25]. Binding to non-targeted quadruplex sequences results in compound loss and may 
have unintentional effects on regulation of non-targeted genes. Increasing selectivity of 
telomerase inhibitors for their targets is therefore an important focus of research.  
DB 832 is a heterocyclic diamidine that has been shown in Chapter 3 to bind to 
human telomeric DNA as a stacked species. Regardless of the starting conformation of 
the human telomeric DNA, DB 832 is capable of inducing the formation of a mixed 
parallel/antiparallel hybrid quadruplex structure, and can even induce formation of this 
structure in the absence of salt. In this chapter, the selectivity of this compound for its 
DNA target will be investigated. Thermal melting will be used to quantify the selectivity 
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of DB 832 for quadruplex vs. duplex DNA binding. Circular dichroism will be used to 
determine selectivity for DB 832 binding as a stacked species to the mixed 
parallel/antiparallel hybrid DNA structure formed by the human telomere. CD studies 
will also be used to investigate the binding of analogs and derivatives of DB 832 to the 
human telomere to help better understand how the structural features of DB 832 
contribute to its selectivity for binding as a stacked species. 
Materials and Methods 
Sample Preparation 
The oligonucleotides d[AG3(T2AG3)3], d(G3CGCG3AG2A2T2G3CG3), 
d(AG3TG4AG3TG4A), d[A3(G3T2A)3G3A2], d[G4(T4G4)3], d[(T2G4)4], 
d(G2T2G2TGTG2T2G2), d (GC)7, d (GCGTTAACGC), d(CGAGATCAAAAGATCTCG) 
and d(TG4T) were purchased with HPLC purification from Midland Certified Reagent 
Company or Integrated DNA Technologies, Inc. The G-quadruplex DNA samples were 
dissolved in buffer to the desired concentrations, heated to 85 0C and cooled slowly to 
insure the folding of the quadruplexes prior to each experiment. The concentration of 
each DNA sample was determined spectrophotometrically at 260 nm using the nearest 
neighbor extinction coefficient at 80°C and extrapolated to 20°C. A stock solution 
containing 1 mM of each compound was prepared in double distilled water and diluted to 
working concentrations immediately before use with buffer. The synthesis of all DB 
compounds will be described elsewhere.  
Thermal Denaturation Studies 
Thermal denaturation studies were conducted on a Cary Varian 300 BIO UV-
visible spectrophotometer in quartz cells with a 1 cm pathlength. A thermistor fixed into 
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a reference cuvette was used to monitor the temperature. The absorbance of the human 
telomeric oligomer d[AG3(T2AG3)3] was monitored at 295 nm, while the hairpin duplex 
sequence d(CGAGATCAAAAGATCTCG) was monitored at 260 nm. Melting curves 
were obtained for both DNA sequences in the presence and absence of DB 832. For both 
oligomers the DNA concentration was 2.7 x 10-6 M and the DB 832: DNA ratio was 2:1. 
Data manipulation and plotting was performed using the program Kaleidagraph version 
3.6. 
CD Measurements 
CD measurements were performed at 20°C in a 10 mM HEPES buffer (pH 7.4) 
containing 3 mM EDTA and 50 mM KCl, except the CD titration with d(TG4T), which 
was prepared in phosphate buffer containing 50 mM KCl, 10 mM K2HPO4 and 0.1 mM 
EDTA. CD spectra were recorded using a Jasco J-810 spectrapolarimeter in a 1-cm cell 
using an instrument scanning speed of 50 nm/min with a response time of 1 s. The 
spectra were averaged over four scans. A buffer baseline scan was collected in the same 
cuvette and subtracted from the average scan for each sample. Appropriate amounts of 
stock solution of compound were added sequentially to increase the molar ratio. Data 
manipulation and plotting was performed using the program Kaleidagraph version 3.6. 
Results and Discussion 
DB 832 is Highly Selective for Quadruplex DNA over Duplex DNA 
In order to determine the selectivity of DB 832 for human telomeric DNA over 
duplex DNA, melting curves were obtained for the intramolecular human telomeric 
sequence d[AG3(T2AG3)3] as well as a random sequence hairpin duplex 
d(CGAGATCAAAAGATCTCG) (Figure 4.1). The melting temperature of the telomeric 
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DNA in the absence of DB 832 is 59.6 °C. Upon addition of DB 832, the melting 
temperature of the DNA increases by approximately 10°C, indicating that the compound 
is stabilizing the quadruplex conformation of the DNA. This is comparable to the ∆Tm 
for the human telomere in the presence of the well-studied porphyrin compound, 
TMPyP4, under similar conditions [26]. In contrast, when DB 832 is added to the duplex 
sequence at the same ratio and conditions, there is no detectable change in Tm. This 
indicates that DB 832 binds much more strongly to quadruplex than to mixed-sequence 
duplex DNAs, making it ideal for further study as a highly selective G-quadruplex 
interactive compound. 
DB 832 Binds Selectively to Mixed Parallel/Antiparallel Hybrid Quadruplex DNA 
DB 832 has been shown to bind to or induce the formation of a mixed 
parallel/antiparallel conformation of human telomeric DNA (Chapter 3). To determine if 
the stacked binding of this compound is selective for this particular DNA structure, CD 
spectra were obtained for DB 832 added to DNA sequences that form a variety of 
structures, including antiparallel chair and basket quadruplexes, a parallel quadruplex, an 
intermolecular quadruplex sequence, and duplex DNA sequences. 
Thrombin Binding Aptamer, d(G2T2G2TGTG2T2G2), forms an antiparallel chair-
type quadruplex as determined by NMR [27]. Before the addition of DB 832, the 
spectrum in the DNA wavelength region has a maximum at 295 nm, with a minimum at 
260 nm, confirming the presence of the antiparallel (chair) conformation (Figure 4.2). 
The addition of DB 832 increases the signal at 260 nm and decreases the signal at 295 
nm, indicating a conformation change in the DNA as the compound binds. In the 
wavelength region of DB 832 absorbance, a slight induced exciton splitting is observed, 
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but only after the compound: DNA ratio reaches 8:1. Compound concentrations this high, 
however, are not biologically relevant and would not be observed in therapeutic use of 
the compound. 
The oligomer d[(G2T4)3G2] has been characterized as a basket-type antiparallel 
quadruplex by 1-D NMR [28]. Before the addition of DB 832, the spectrum in the DNA 
wavelength region has a maximum at 295 nm, and a minimum at 260 nm, indicative of an 
antiparallel conformation of DNA (Figure 4.3). The addition of DB 832 does not cause a 
significant change in the shape of the spectra in the DNA region, indicating that DB 832 
does not significantly rearrange the conformation of the DNA. No induced exciton 
splitting is observed in the wavelength region of DB 832 absorbance, indicating that 
binding is occurring as a monomer and not a stacked species. 
The G-rich strand of the promoter region of the c-MYC oncogene, 
d(AG3TG3TAG3TG3T), forms a parallel propeller-type quadruplex in solution [29]. 
Before the addition of DB 832, the spectrum in the DNA wavelength region has a 
maximum at 260 nm, consistent with a parallel conformation of DNA (Figure 4.4). The 
addition of DB 832 causes a decrease in signal at 260 nm, but still results in a positive 
peak at that wavelength, indicating that DB 832 does not significantly rearrange the 
conformation of the DNA. No induced exciton splitting is observed in the wavelength 
region of DB 832 absorbance, indicating that binding is occurring as a monomer and not 
a stacked species. 
d(TG4T) forms a four-stranded intermolecular quadruplex [30]. The addition of 
DB 832 does not change the CD spectrum of this DNA, suggesting that this compound 
does not bind to intermolecular quadruplexes (Figure 4.5). Binding to intermolecular 
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quadruplexes can result in undesirable genomic effects including end-end fusion of 
chromosomes.  
CD spectra were also obtained with two duplex sequences, an AT-rich sequence, 
d(GCGAATTCGC) (Figure 4.6), and a GC-rich sequence, d (GC)7 (Figure 4.7). AT-rich 
duplexes have been shown to have narrower grooves than GC-rich sequences [31]. In 
both cases, a small induced signal was observed, but the lack of exciton splitting suggests 
that binding as a stacked species is not occurring. 
The absence of any significant exciton splitting when DB 832 is titrated into these 
DNA sequences suggests that DB 832 binds as a stacked species to mixed 
parallel/antiparallel quadruplex DNA with a high degree of selectivity.  
DB 832 Binds Selectively as a Stacked Species to a Mixed Parallel/Antiparallel 
Quadruplex with 5’- Diagonal/Lateral/Lateral-3’ Loop Orientation 
In order to further examine the selectivity of DB 832 for the mixed 
parallel/antiparallel type of quadruplex structure, CD spectra were obtained for DB 832 
with other DNA sequences that form hybrid quadruplex structures in solution.  
Tel26, d[A3(G3T2A)3G3A2], is a modified human telomeric sequence that has a 
mixed parallel/antiparallel hybrid structure as determined by NMR [32]. The structure of 
this sequence is identical to the hybrid conformation of the unmodified human telomere 
(Tel22) in the presence of postassium [18]. The CD spectrum of this sequence (Figure 
4.8) has peaks at both 260 and 295 nm, suggesting the DNA has a hybrid structure, which 
is consistent with the NMR data. Upon addition of DB 832, the CD signal at both peaks 
initially increases slightly (up to a 2:1 compound:DNA ratio), then decreases, resulting in 
a final conformation similar in shape to the initial conformation, indicating that DB 832 
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does not cause significant rearrangement of DNA conformation upon binding. In the 
wavelength region of DB 832 absorbance, induced exciton splitting is observed, 
indicating that the compound is binding to this sequence as a stacked species. 
Two other quadruplex DNA sequences have been shown by NMR to form mixed 
parallel/antiparallel structures in solution. bcl2MidG4Pu23-G15T/G16T, 
d(G3CGCG3AG2A2T2G3CG3), is a dual mutant sequence that forms the major quadruplex 
product found in the promoter region of the bcl-2 proto-oncogene sequence [15, 16]. 
Before the addition of DB 832, the spectrum in the DNA wavelength region has peaks at 
both 260 and 295 nm (Figure 4.9), suggesting the DNA has a mixed parallel/antiparallel 
structure, which is consistent with the NMR structure and previously published CD data 
[15, 16]. However, the 260 nm peak is larger relative to the 295 nm peak than is seen 
with the Tel22 or Tel26 sequences. The addition of DB 832 doesn’t significantly change 
the shape of the spectra in the DNA region, indicating that the compound does not change 
the conformation of the DNA upon binding. In the wavelength region of DB 832 
absorbance, a small induced CD signal is observed. However, the absence of exciton 
splitting indicates that the compound is likely binding as a monomer and not a stacked 
species.  
The Tetrahymena telomeric sequence, d(T2G4)4,  has also been shown by NMR to 
form a mixed parallel/antiparallel quadruplex structure [10]. Before the addition of DB 
832, the spectrum in the DNA wavelength region has peaks at both 260 and 295 nm, 
consistent with the formation of a mixed parallel/antiparallel structure. Like the bcl-2 
proto-oncogene sequence, the signal at 260 nm is large relative to the signal at 295 nm. 
Upon addition of DB 832, the peak at 260 nm shifts to higher wavelength and has a large 
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decrease in magnitude (Figure 4.10). The presence of a residual peak suggests that the 
final structure is still a mixed hybrid conformation. An induced exciton is seen in the 
wavelength region of DB 832 absorbance. However, it is much smaller in magnitude than 
the signal seen when DB 832 is titrated with either Tel22 or Tel26. 
Although these two sequences form mixed parallel/antiparallel hybrid quadruplex 
structures, they are not identical to the hybrid conformation formed by the human 
telomeric sequences Tel22 and Tel 26 [18, 32]. The three loops of the Tel22 and Tel26 
sequences are oriented diagonal/lateral/lateral as read from the 5’ to 3’ direction. The 
loops of the TetTel and bcl2MidG4Pu23-G15T/G16T sequences are oriented 
lateral/lateral/diagonal from 5’ to 3’. These two sequences also have a different pattern of 
glycosidic orientation of the sugars than Tel22 and Tel26. The relative difference in 
magnitude of the CD signals at 260 nm vs. 295 nm for TetTel and bcl2MidG4Pu23-
G15T/G16T as compared to Tel22 and Tel26 may be indicative of this difference in 
structure. If this is the case, the fact that the addition of DB 832 to TetTel results in a 
smaller signal at 260 nm as compared to 295 nm, suggests that DB 832 may be inducing 
a conformation change of TetTel from a 5’-lateral/lateral/diagonal-3’ hybrid to a  5’-
diagonal/lateral/lateral-3’ hybrid quadruplex. The small amount of exciton splitting seen 
with this sequence may be due to DB 832 binding as a stacked species to the rearranged 
conformation. 
These results suggest that DB 832 binds selectively as a stacked species to the 
specific 5’-diagonal/lateral/lateral-3’ type of mixed parallel/antiparallel structure formed 
by the human telomere and modified human telomeric sequences.  
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Recognition of Quadruplex DNA as a Stacked Species is Sensitive to Compound 
Structure 
A series of DB 832 analogs was studied to determine how structural variations 
affect binding as a stacked species to the human telomere. The induced exciton CD signal 
is sensitive to the relative placement of the heterocyclic rings on the compound. DB 1093 
is an isomer of DB 832 in which the furan groups are not adjacent. This compound does 
not exhibit any change in CD signal when titrated into human telomeric DNA (Figure 
4.11). This suggests that recognition of the quadruplex grooves may occur via a 
bifurcated hydrogen bond between the two adjacent furan oxygens and a G-NH2 amino 
group hydrogen in the quadruplex grooves.  
DB 914, a derivative of DB 832 with an additional phenyl ring, exhibits a similar, 
but somewhat weaker, CD pattern than DB 832 when titrated into human telomeric DNA 
(Figure 4.12). This observation further suggests that the adjacent furans are involved in 
H-bonding interactions for recognition of quadruplex grooves. Additional recognition 
sites between DB 832 and DB 914 and the quadruplex groove may arise from hydrogen 
bonding between N3 of the guanine and an amidine hydrogen from the DB 832 molecule, 
as well as electrostatic interaction between amidines and phosphate groups on the DNA 
backbone. DB 1324 is an analog of DB 914 in which the amidine groups are replaced 
with guanidinium groups. When DB 1324 is titrated into human telomeric DNA, large 
changes in the CD spectra occur in the DNA region, suggesting a major structural change 
is occurring in the DNA (Figure 4.13). However, no exciton splitting in the induced 
region occurs, suggesting that this compound binds as a monomer. This further suggests 
that the amidine groups are involved in recognition of the groove as a stacked species.  
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Thiophene analogs of DB 832 and DB 914 were also studied. DB 1438 (Figure 
4.14) and DB 1463 (Figure 4.15) are DB 832 analogs that have one furan replaced by a 
thiophene, and DB 1450 (Figure 4.16) is a DB 832 analog with both furans replaced by 
thiophenes. DB 1255 (Figure 4.17) is a dithiophene analog of DB 914. Sulfur is not as 
electronegative as oxygen and therefore has weaker hydrogen bonding interactions than 
oxygen. All four sulfur analogs exhibit a smaller magnitude of exciton splitting than the 
respective bifuryl compounds, which may be due to lower binding affinity from 
decreased hydrogen-bonding interactions or from decreased stacking interactions due to 
the slight change in the curvature of the compounds. However, the disubstituted DB 1450 
has a significantly higher amount of exciton splitting than the monosubstituted 
compounds DB 1438 and DB1463. Thiophene compounds are known to have better 
stacking properties than furan, which may account for this difference. 
Other bifuryl compounds were studied, including DB 1256 (Figure 4.18), DB 
1246 (Figure 4.19), DB 934 (Figure 4.20) and DB 1003 (Figure 4.21) None of these 
compounds exhibited exciton splitting with human telomeric DNA at a 4:1 
compound/DNA ratio. DB 934 and 1246 are analogs of DBA 832 and DB 914, 
respectively, in which a pyridine has been substituted for the phenyl ring. The fact that 
substitution of a single atom eliminates the stacking interaction of the compound shows 
that recognition of the quadruplex groove as a stacked species is extremely sensitive to 
the compound structure. 
CD titrations with human telomeric DNA were also performed with the trifuran 
compounds DB 657 (Figure 4.22), DB 659 (Figure 4.23), and DB 1315 (Figure 4.24). DB 
1315 is the only one that exhibits exciton splitting. It has an amidine-phenyl-furan-furan 
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arrangement. Every compound studied that contained this motif exhibited some degree of 
exciton splitting. This sequence of heterocycles could serve as a starting point for the 
design of other compounds that recognize quadruplex DNA as a stacked species.   
Conclusions 
The unique structural features of quadruplexes present an opportunity to target 
DNA in a structure-specific manner, leading to increased selectivity for quadruplex over 
duplex DNA, as well as selectivity for a particular quadruplex structure over other 
quadruplexes. Selectivity of a compound for its target quadruplex structure is important 
in order to reduce cytotoxicity from duplex-binding as well as prevent drug loss from 
binding to non-targeted quadruplex sites. 
DB 832 is a heterocyclic diamidine that binds to human telomeric DNA as a 
stacked species. It is highly selective for quadruplex binding, showing virtually no 
binding to duplex DNA. DB 832 also binds very selectively as a stacked species to the 
5’-diagonal/lateral/lateral-3’ hybrid quadruplex structure which is preformed or induced 
by DB 832 in human telomere and modified human telomeric DNA sequences. The 
induced CD signals produced by DB 832 are very sensitive to DNA and compound 
structure. DB 832 does not exhibit exciton splitting with either AT- or GC-rich duplex 
DNA sequences (d[GCGAATTCGC] and d[(GC)7], respectively) nor does it exhibit any 
significant induced CD signal with sequences that form parallel (c-MYC), antiparallel 
chair (TBA), antiparallel basket (d[(G2T4)3G2]) or intermolecular (TG4T) quadruplexes or 
with the 5’-lateral/lateral/diagonal-3’ hybrid structure formed by bcl2MidG4Pu23-
G15T/G16T. DB 832 does induce a small amount of exciton splitting with TetTel which 
forms the 5’-lateral/lateral/diagonal-3’ hybrid quadruplex. However, the change in CD 
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signal in the DNA region suggests that DB 832 may be inducing a conformation change 
to the 5’-diagonal/lateral/lateral-3’ hybrid, consistent with the selectivity of DB 832 
binding as a stacked species to this particular quadruplex conformation.  
Circular dichroism studies with a series of DB 832 analogs show that the binding 
mode of these compounds is very sensitive to the relative placement and orientation of 
the heterocyclic systems. The results suggest that this series of compounds must contain 
two adjacent furan groups, possibly for H-bonding recognition of the grooves as a 
stacked species. Additional recognition sites between DB 832 and the quadruplex groove 
may arise from hydrogen bonding between N3 of the guanine and an amidine hydrogen 
from the DB 832 molecule, as well as electrostatic interaction between amidines and 
phosphate groups on the DNA backbone. NMR studies to determine the orientation of the 
DB 832 molecules relative to quadruplex groove are currently in progress.  
The unique binding mode of DB 832 as well as its selectivity for its DNA target 
may allow it to serve as the starting point for the design of a new class of highly selective 
groove-binding molecules. Nonintercalating, stacked species are of particular interest for 
recognition of quadruplexes since studies with duplex DNAs show that compounds that 
bind as stacked dimers have increased binding affinity and selectivity over similar 
compounds that bind as monomers. Similar stacking in the grooves of quadruplex DNA 
structures would appear to be a favorable way to selectively recognize quadruplexes with 
optimum interactions, perhaps employing an induced fit component, between the stacked 
heterocycles and the G bases of the quadruplex tetrads.  
Potentially, the individual monomer units could be covalently linked, dramatically 
increasing the affinity and selectivity of the compound for human telomeric DNA, 
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leading to enhanced telomerase inhibition and anti-protozoan activity with decreased 
cytotoxic side effects. 
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Figure 4.1 UV melting profiles of the human telomere sequence, d[AG3(T2AG3)3], 
monitored at 295 nm (top) and the hairpin duplex, d(CGAGATCAAAAGATCTCG), 
monitored at 260 nm (bottom) in the absence and presence of DB 832 in 50 mM KCl. 
DNA concentration was 2.7 µM and DB 832:DNA ratio was 2:1 for both DNAs. DB 832 
increases the melting temperature of the human telomere sequence by approximately 
10°C, while it has a negligible effect on the melting temperature of the duplex sequence.  
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Figure 4.2 CD spectra of DB 832 titrated into 2.3 µM Thrombin Binding Aptamer, 
d(G2T2G2TGTG2T2G2), in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 2:1 to 16:1. 
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Figure 4.3 CD spectra of DB 832 titrated into 2.7 µM d(G2T4)3G2, in HEPES buffer 
containing 50 mM KCl. Compound:DNA ratios ranged from 2:1 to 16:1 
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Figure 4.4 CD spectra of DB 832 titrated into 3.4 µM Pu18, promoter region of the c-
MYC oncogene, d(AG3TG3TAG3TG3T), in HEPES buffer containing 50 mM KCl. 
Compound:DNA ratios ranged from 2:1 to 16:1.  
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Figure 4.5 CD spectra of DB 832 titrated into d[TGGGGT] (single strand conc. 16 µM) 
in phosphate buffer containing 70 mM K+. Compound:DNA ratios ranged from 1:1 to 
5:1. 
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Figure 4.6 CD spectra of DB 832 titrated into 4.6 µM d[GCGAATTCGC] in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
 
 
 
 
 
 
 
 
  146   
 
-20
-15
-10
-5
0
5
10
15
250 300 350 400 450 500 550
DNA-buffer
1:1-buffer
2:1-buffer
3:1-buffer
4:1-buffer
5:1-buffer
C
D
 (m
de
g)
wavelength (nm)
 
 
Figure 4.7 CD spectra of DB 832 titrated into 5.6µM d[(GC)7] in HEPES buffer 
containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 5:1. 
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Figure 4.8 CD spectra of DB 832 titrated into 3.1 µM Tel26 modified human telomeric 
sequence, d[A3(G3T2A)3G3A2], in HEPES buffer containing 50 mM KCl. 
Compound:DNA ratios ranged from 1:1 to 9:1.  
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Figure 4.9 CD spectra of DB 832 titrated into 2.3 µM bcl2MidG4Pu23-G15T/G16T, 
d(G3CGCG3AG2A2T2G3CG3), a dual mutant sequence that forms the major quadruplex 
product found in the promoter region of the bcl-2 proto-oncogene sequence, in HEPES 
buffer containing 50 mM KCl. Compound:DNA ratios ranged from 1:1 to 10:1 
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Figure 4.10 CD spectra of DB 832 titrated into 3.9 µM Tetrahymena telomeric sequence, 
d(T2G4)4, in HEPES buffer containing 50 mM KCl. Compound:DNA ratios ranged from 
1:1 to 14:1.  
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Figure 4.11 CD spectra of DB 1093 titrated into 3.8 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.12 CD spectra of DB 914 titrated into 3.5 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 6:1. 
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Figure 4.13 CD spectra of DB 1324 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 8:1. 
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Figure 4.14 CD spectra of DB 1438 titrated into 5.1 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 16:1. 
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Figure 4.15 CD spectra of DB 1463 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 9:1. 
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Figure 4.16 CD spectra of DB 1450 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 9:1. 
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Figure 4.17 CD spectra of DB 1255 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
 
 
 
  157   
-2
0
2
4
6
8
10
12
250 300 350 400 450 500 550
DNA-buffer
1:1-buffer
2:1-buffer
3:1-buffer
4:1-buffer
C
D
 (m
de
g)
wavelength (nm)
 
 
O O
NH2N
NH2
+
HN
N
NH2
H2N +  
 
 
Figure 4.18 CD spectra of DB 1256 titrated into 3.7 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.19 CD spectra of DB 1246 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.20 CD spectra of DB 934 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.21 CD spectra of DB 1003 titrated into 3.3 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.22 CD spectra of DB 657 titrated into 3.7 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 6:1. 
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Figure 4.23 CD spectra of DB 659 titrated into 3.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 4:1. 
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Figure 4.24 CD spectra of DB 1315 titrated into 2.6 µM human telomeric sequence, 
d[AG3(T2AG3)3], in HEPES buffer containing 50 mM KCl. Compound:DNA ratios 
ranged from 1:1 to 5:1. 
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Chapter 5 
Binding of Modified Porphyrins and Sapphyrins to Quadruplex DNA:  
SPR-Biosensor Studies 
Introduction 
Porphyrins are a class of heterocyclic macrocycles composed of pyrrole subunits 
linked through methine bridges. Cationic porphyrins are known to bind to and stabilize 
different types of G-quadruplexes and, in some cases, to facilitate G-quadruplex 
formation [1-5]. 5,10,15,20-tetra-(N-methyl-4-pyridyl)porphine (TMPyP4) is a 
commercially-available cationic porphyrin that has been widely studied and shown to 
bind to quadruplex DNA sequences (Figure 5.1). TMPyP4 has been shown 
experimentally to bind to human telomeric DNA with a 2:1 stoichiometry [6]. Molecular 
modeling with human telomeric DNA suggests that one TMPyP4 molecule is stacked 
externally on each of the terminal quartets, with the positively charged groups oriented 
toward the sugar-phosphate DNA backbone [2]. TMPyP4 has been shown to stabilize the 
quadruplex conformation of telomeres, preventing recognition of the telomere by 
telomerase and resulting in effective inhibition of the enzyme [3, 7]. TMPyP4 also binds 
to and stabilizes the G-rich strand of the intramolecular c-MYC sequence with a 2:1 
stoichiometry, with each molecule stacked externally on the G-quartet surface, in a 
similar manner as TMPyP4 binds to the human telomere [4]. However, when TMPyP4 
binds to c-MYC, it induces a conformation change in the DNA to a mixed 
parallel/antiparallel structure. This conformational change of the DNA renders the 
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accessory protein NM23-H2 unable to recognize the NHEIII1 and convert it to the 
transcriptionally active form, which leads to repression of transcriptional activity [8] and 
inhibition of tumor growth in vivo [9]. 
Despite the effective quadruplex-binding and enzyme inhibition exhibited by 
TMPyP4, this compound has several drawbacks that would prevent it from being used 
therapeutically. Porphyrins are known to produce photoinduced cytotoxicity [10, 11]. 
Upon excitation, singlet oxygen is generated, resulting in indiscriminant cell damage. 
This feature of porphyrins has been exploited advantageously through the use of 
photodynamic therapy for treatment of some cancers including lung, esophageal and 
bladder cancers [12]. However, the phototoxicity of porphyrins would prevent them from 
being used as telomerase inhibitors or c-MYC repressors. TMPyP4 also binds 
preferentially to intermolecular quadruplexes over the biologically relevant 
intramolecular quadruplexes. This intermolecular binding has been demonstrated through 
the TMPyP4-induced formation of anaphase bridges in sea urchins [3]. Binding to 
intermolecular quadruplexes not only results in compound loss due to binding of non-
targeted sequences, but is undesirable because it can result in end-to-end fusion of 
chromosomes. Also, the binding of TMPyP4 to the human telomere and c-MYC 
sequence is not as strong as some of the newer quadruplex-interactive compounds which 
have been discovered. The porphyrin core of TMPyP4 is smaller (10.1 Å) than the size of 
the G-quartet (13.2 Å) which results in the molecule binding with an offset from the 
center of the quartet [2].  TMPyP4 only overlaps with two out of four of the guanines in 
the terminal G-quartets. The binding of TMPyP4 to the quadruplex could potentially be 
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improved if it were modified to increase the contact surface between the compound and 
the G-quartets, in order to maximize stacking interactions. 
Telomestatin (Figure 5.1), a natural product isolated from Streptomyces anulatus 
3533-SV4 [13], has a larger ring system than TMPyP4. The ring system is similar in size 
to the G-quartet structure (Figure 5.1) which increases π-π stacking, electrostatic and 
hydrogen-bonding interactions as compared to TMPyP4. Telomestatin has been shown to 
bind strongly to and stabilize intramolecular basket-type G-quadruplex structures [14]. 
Telomestatin is also able to induce and stabilize G-quadruplexes in the absence of added 
monovalent cations, which is a unique characteristic among small molecules [14]. DB 
832 is the only other G-quadruplex-interactive compound that has been shown to induce 
quadruplex formation in the absence of salt. Modeling studies of Telomestatin suggest 
that it binds to the ends of the basket conformation of the intramolecular human telomeric 
sequence with a 2:1 stoichiometry [15].Telomestatin is the strongest telomerase inhibitor 
ever reported of any G-quadruplex interactive small molecule, with an IC50 of .005 µM 
[16]. In comparison, TmPyP4 has an IC50 of 0.63 µM [3]. Telomestatin is also a very 
specific inhibitor of telomerase. It does not inhibit other DNA polymerases or reverse 
transcriptases [16].Telomerase is also 70 times more selective for binding to quadruplex 
DNA over duplex DNA [14], likely due to the close match between the size and shape of 
the macrocyclic structure of telomestatin to that of the G-quartet. This is important 
because indiscriminant duplex binding is associated with cytotoxicity. 
Since Telomestatin is a natural product, it is very difficult to obtain, especially in 
quantities needed for widespread therapeutic use. Its complicated ring system is difficult 
to synthesize, and at present would be cost-prohibitive to produce commercially. Also, 
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since telomestatin is an uncharged molecule, it has low solubility in water, which is not 
only undesirable from a therapeutic standpoint, but also makes it difficult to study. The 
ease of synthesis of porphyrins and the ability to create modified porphyrins with 
different ring systems and substituents as well as their solubility makes porphyrins 
desirable to work with from a drug design standpoint. On the basis of modeling and 
comparative analysis of the binding of TMPyP4 and telomestatin to G-quadruplex, a 
series of metal-substituted porphyrins and expanded porphyrins, (Figure 5.2), were 
designed and synthesized by Dr. Laurence Hurley’s research group at the University of 
Arizona. The larger ring systems were designed to overlap the G-quartet more effectively 
than the ring system of TMPyP4, in hopes of improving binding and selectivity. The 
substitution of metals in the porphyrin cores eliminates the photocytotoxicity associated 
with porphyrins through rapid quenching of singlet oxygen [10, 11]. To investigate the 
effect of these modifications on binding and selectivity, surface plasmon resonance (SPR) 
was used to quantify the interactions between TMPyP4 as well as the modified 
compounds with different quadruplex DNA sequences. 
Materials and Methods 
Sample Preparation 
The oligonucleotides 5’-biotin-d[AG3(T2AG3)3], 5’-biotin-d(AG3TG4AG3TG4A), 
5’-biotin-d(CGAATTCG), 5’-biotin-d[(G2T4)3], 5’-biotin-d[(T2G4)4], and 5’-biotin-
d(G2T2G2TGTG2T2G2) were purchased with HPLC purification and mass spectrometry 
characterization from Midland Certified Reagent Company. TMPyP4 was purchased 
from Midcentury. Stock solutions containing 1 mM of each compound were prepared in 
double distilled water and diluted to working concentrations immediately before use with 
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buffer. S2SAP, Se2SAP, Se2Py3, SHPy3, SeHPy3, and S2Py3 were synthesized by Dr. 
Laurence H. Hurley’s group at the University of Arizona. The synthesis of Se2SAP has 
been previously described [17]. The synthesis of the other modified porphyrin 
compounds will be described elsewhere. 
Immobilization of DNA and Biosensor SPR Experiments 
 Biosensor SPR experiments were performed with a four-channel BIAcore 3000 
optical biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips (BIAcore 
SA with linked streptavidin). All DNA samples, for either duplex- or quadruplex-binding 
experiments, were used as single strands (fold-back structures) to prevent dissociation in 
the SPR flow system. The concentration in all cases refers to the strand concentration, 
which is also the duplex or quadruplex concentration. The chips were prepared for use by 
conditioning with three to five consecutive 1 min injections of 1 M NaCl in 50 mM 
NaOH followed by extensive washing with buffer. 5'-Biotinylated DNA samples (25 nM) 
in HBS buffer were immobilized on the flow cell surface by noncovalent capture as 
previously described [18-22]. Three flow cells were used to immobilize DNA oligomer 
samples, and a fourth cell was left blank as a control. Interaction analysis was performed 
by using both kinetics and steady-state methods with multiple injections of different 
compound concentrations over the immobilized DNA surface at 25 ºC. DNA-binding 
experiments were performed in sterile filtered and degassed HBS buffers: 0.01 M 
HEPES, (pH 7.4), 3 mM EDTA, and 0.005% surfactant P20 with either 0.1 M KCl, 0.2 
M KCl, 0.1 M NaCl, or 0.2 M NaCl. Compound solutions were prepared in the desired 
buffer by serial dilutions from stock solution and injected from 7 mm plastic vials with 
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pierceable plastic crimp caps (BIAcore, Inc.). To remove any remaining bound 
compound after the dissociation phase of the sensorgram, a low-pH glycine regeneration 
buffer was used (10 mM glycine at pH 2). The baseline was then reestablished, and the 
next compound concentration sample was injected.  
The instrument response (RU) in the steady-state region is proportional to the 
amount of bound drug and was typically determined by linear averaging over a 10-20 s or 
longer time span, depending on the length of the steady-state plateau. The predicted 
maximum response per bound compound in the steady-state region (RUmax) was 
determined from the DNA molecular weight, the amount of DNA on the flow cell, the 
compound molecular weight, and the refractive index gradient ratio of the compound and 
DNA, as previously described [23]. In most of the cases, the observed RU values at high 
concentrations were greater than RUmax, pointing to more than one binding site in these 
DNA sequences. The number of binding sites was estimated fitting plots of RU versus 
Cfree. These methods can also be used to determine an empirical RUmax value. The RUmax 
value is required to convert the observed response (RU) to the standard binding 
parameter r (moles of drug bound per moles of DNA hairpin) 
r = RU/RUmax 
 
which is useful for comparison of a compound binding to different DNAs. To obtain the 
affinity constants, the data were fitted to the following interaction model using 
Kaleidagraph for nonlinear least-squares optimization of the binding parameters: 
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r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2) 
 
where K1 and K2 are equilibrium constants for two types of binding sites and Cfree is the 
concentration of the compound in equilibrium with the complex and is fixed by the 
concentration in the flow solution. For a single dominant binding site model, K2 is equal 
to zero. Errors in fitting two K values within any experiment were ±10%, while errors in 
K values in replicate experiments were ±25%. Errors in fitting results that required only a 
single K value were ±10%. 
After injection of the compound and prior to reinjection of buffer, the association 
kinetics of compound binding to immobilized DNA can be monitored, and after 
reinjection of buffer the dissociation kinetics can be determined. To minimize possible 
mass transport effects, SPR kinetics experiments were conducted at flow rates of 50-100 
µL/min with low surface densities of immobilized DNA. Global fitting (BIA Evaluation 
Software, BIAcore, Inc.) of the association and dissociation curves was done in a 
concentration range where the compound binds significantly only to the strongest binding 
site: up to 400 nM for G2T4 and 100 nM for TetTel and TBA. Both the association rate 
constant, ka, and the dissociation rate constant, kd, could be obtained for these complexes, 
and the calculated equilibrium constant (Kkin = ka/kd) was within a factor of 2 of the 
steady-state value. For binding of Se2SAP to duplex DNAs, the kinetics of association 
and dissociation are too fast for accurate analysis by SPR methods. For binding of the 
compound to the c-MYC sequence, we were unable to obtain satisfactory global fits, on 
the basis of the analysis of residuals and quality of fit values, for the lowest 
concentrations required in the 1:1 binding region with this strong interaction. In the low-
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concentration c-MYC association region, the curves were initially slightly concave, 
which may be due to a fraction of the compound adsorbing to the flow system at 
injection. This problem becomes much less significant at the higher concentrations used 
for the weaker binding DNAs. Since the compound is discarded on dissociation, the 
adsorption problem is less significant, and a kd value can be accurately determined for the 
c-MYC complex. With the steady-state K and the kd value, a ka value can be calculated, 
but with less confidence than for the experimentally determined values.  
Results 
SPR Screening of Modified Porphyrins 
Surface plasmon resonance (SPR) is a useful technique for the screening of small 
molecules in order to determine their relative binding affinities and selectivity for a target 
DNA sequence. TMPyP4 and the modified porphyrins were evaluated against a 19-mer 
c-MYC sequence, d(AG3TG4AG3TG4A), and the human telomeric sequence, 
d[AG3(T2AG3)3], using SPR. These two oligonucleotides were immobilized in different 
flow cells on the same sensor chip, and a range of compound concentrations were 
injected to monitor the interactions with DNA. Suitable blank control injections with 
running buffer (HEPES buffer containing 200 mM KCl at pH 7.4) were also performed, 
and the resulting sensorgrams were subtracted from the compound sensorgrams to obtain 
the final concentration-dependent graphs. The binding stoichiometry arises naturally from 
the RU as saturation of binding sites is approached in SPR experiments. During SPR 
titration, the increase of RU values is directly proportional to the amount of drug bound 
to DNA molecules immobilized on the sensor chip. The plot of RU versus the unbound 
concentration of each of the compounds was fitted to a two-site binding model 
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(Experimental Section). Direct steady-state binding plots were constructed by averaging 
the observed SPR responses in the steady-state region, and the responses were plotted 
against the free compound concentration in the flow solution. The binding plots for the 
concentration-dependent binding of the porphyrins on the c-MYC sequence and the 
telomeric DNA are shown in parts A and B, respectively, of Figure 5.3. The equilibrium 
binding constants (K values) are shown for each compound in Table 5.1. Only TMPyP4 
exhibited two strong binding sites with each sequence. The other compounds exhibited 
weaker, secondary binding with K2 values (not shown) at least ten times lower than K1. 
Of the compounds studied, a diseleno sapphyrin compound, Se2SAP, had the strongest 
binding to both the c-MYC sequence (K = 6.2 x 107 M-1) and to the human telomeric 
sequence (K = 1.01 x 107 M-1). This compound represents a significant improvement in 
binding to these sequences over TMPyP4. TMPyP4 binds to c-MYC at two sites, with K1 
= 1.4 x 107 M-1 and K2 = 5.4 x 106 M-1 and to the human telomere, with K1 = 3.5 x 106 M-
1 and K2 = 3.7 x 105 M-1. These results are in agreement with polymerase stop assay 
results from Laurence Hurley’s group at the University of Arizona which shows that 
Se2SAP binds more strongly to the c-MYC sequence than TMPyP4 or the other modified 
porphyrins (unpublished data). On the basis of these results, Se2SAP was chosen for 
further study using SPR. 
Selectivity of Se2SAP for the c-MYC Sequence over Duplex DNA by Surface 
Plasmon Resonance Experiments 
Surface plasmon resonance (SPR) experiments were conducted to independently 
determine the selectivity of binding of Se2SAP with the 19-mer c-MYC sequence relative 
to a duplex sequence (CGAATTCG, as a hairpin duplex). These two oligonucleotides 
  177   
were immobilized in different flow cells on the same sensor chip, and a range of Se2SAP 
concentrations were injected to monitor the interactions with DNA. Suitable blank 
control injections with running buffer (HEPES buffer containing 200 mM KCl at pH 7.4) 
were also performed, and the resulting sensorgrams were subtracted from the compound 
sensorgrams to obtain the final concentration-dependent graphs. Sensorgrams [resonance 
units (RU) versus time] for the concentration-dependent binding of Se2SAP on the c-
MYC sequence and the duplex DNA are shown in parts A and B, respectively, of Figure 
5.4. The plot of RU versus the unbound concentration of Se2SAP was fitted to the 
binding models with one or two binding sites (Experimental Section). The best fit to the 
interaction results for the c-MYC sequence is for a single, strong binding site, and the 
expected RUmax was obtained for the single binding site (on the basis of the amount of 
DNA on the chip). At higher concentrations, additional Se2SAP binds to the DNA 
through a significantly weaker second site. The binding constant for the second site is 
over a factor of 10 less than for the strong site, and the dissociation rate is much faster, a 
characteristic of weak, nonspecific binding. The measured steady-state equilibrium 
binding constant, K = 6.2 × 107 M-1, indicates the high affinity of Se2SAP for the c-MYC 
sequence. The dissociation rate constant kd = 0.0029 s-1 obtained from the kinetics 
analysis of the sensorgrams also further confirmed the single, strong binding site of 
Se2SAP with the c-MYC G-quadruplex.  
The binding of Se2SAP with the duplex DNA sequence showed much faster 
kinetics (kd > 0.2 s-1) than binding with the c-MYC sequence. The very fast off kinetics 
and the multisite binding at higher concentrations clearly show the nonspecific, weaker 
binding of Se2SAP to the duplex DNA rather than the c-MYC G-quadruplex. The steady-
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state K value calculated for the binding of Se2SAP with duplex is on the order of 106. 
SPR experiments confirm the selectivity (~50-fold) of Se2SAP for the c-MYC G-
quadruplex over the duplex DNA.  
SPR Demonstrates That Se2SAP Binds More Selectively to the c-MYC and Similar 
G-Quadruplexes Than to Other G-Quadruplex Structures.  
Recent studies indicate that biologically relevant parallel c-MYC G-quadruplexes 
can exist as a mixture of four loop isomers [8]. Se2SAP has been shown through 
electromobility shift assays (EMSA) with mutant c-MYC sequences to selectively trap 
out the single-loop hybrid 1:2:1 loop isomer of the G-quadruplex [17]. Circular dichroism 
results suggest that upon binding to Se2SAP, this parallel c-MYC structure is converted 
to a mixed parallel/ antiparallel hybrid structure [17]. The strong binding of this 
molecule, as implied from the modeling studies, and confirmed by SPR suggested that 
this molecule may be selective for this G-quadruplex structure, which has the tetrad 
arrangement syn-anti-anti-anti associated with the one-base lateral loop. To compare the 
selectivity of Se2SAP with the c-MYC G-quadruplex versus other G-quadruplex 
structures, an SPR experiment was performed using three established and different G-
quadruplex-forming sequences. The G2T4 sequence was used to determine the binding of 
Se2SAP to the basket structure. G2T4 is known to form the basket-type G-quadruplex 
structure in both NaCl and KCl solutions [24, 25]. For comparison with the chair-type G-
quadruplex, thrombin-binding aptamer (TBA) was used [26]. Finally, the Tetrahymena 
telomere (TetTel) sequence, which forms a G-quadruplex structure with a mixed 
parallel/antiparallel hybrid structure [27] was used to mimic the G-quadruplex structure 
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formed upon addition of Se2SAP to the parallel c-MYC G-quadruplex. One end of this 
G-quadruplex has a structure with a tetrad arrangement similar to that proposed to be 
trapped out by Se2SAP. The three G-quadruplex-forming oligonucleotides, TetTel, TBA, 
and G2T4, were immobilized in different flow cells on the same sensor chip, and the SPR 
experiments were conducted as described above with a range of Se2SAP concentrations. 
HEPES buffer containing 200 mM KCl or 200 mM NaCl at pH 7.4 was used for all the 
sequences. Since the NMR structure of the mixed parallel/antiparallel G-quadruplex for 
the TetTel sequence was obtained in NaCl [27], the SPR experiment was conducted in 
HEPES buffer containing 200 mM NaCl for the TetTel sequence. The SPR experiment 
showed similar results for the binding of Se2SAP with the TetTel sequence in the 
presence of buffer containing KCl or NaCl. The final concentration-dependent 
sensorgrams for the binding of Se2SAP to these three sequences are shown in Figures 
5.5-5.7. 
In all cases, the G-quadruplexes exhibited two binding sites: a single strong 
binding site and a site that is at least 10-fold weaker. Since the second binding site in all 
cases exhibited much faster dissociation kinetics, which is characteristic of weak, 
nonspecific binding, only the results from the primary strong binding site are considered 
for further discussion. The dissociation rate constant (kd) obtained from the kinetics 
method and the equilibrium binding constant (K) derived from the steady-state method 
for the different sequences are tabulated in Table 5.2 (for comparison, the values for c-
MYC and hairpin duplex DNA are also included). The differences in the dissociation of 
Se2SAP from that of the TetTel, TBA, and G2T4 sequences can be easily visualized from 
their corresponding sensorgrams (Figures 5.5-5.7). Among the G-quadruplexes, the c-
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MYC G-quadruplex showed the highest equilibrium constant (K = 6.2 × 107 M-1) and the 
slowest dissociation rate constant (kd = 0.0029 s-1) indicative of the strongest binding of 
Se2SAP with this sequence. The kinetics (kd = 0.0041 s-1) and the steady-state (K = 4.2 × 
107 M-1) values for the TetTel sequence indicate that Se2SAP also binds very strongly to 
a single site in the double-loop hybrid G-quadruplex with a slightly lower binding 
constant than with the c-MYC G-quadruplex. With the G2T4 sequence, Se2SAP showed a 
much faster dissociation rate (kd value is ~12 times larger than that for the c-MYC 
sequence), and its K value is similar to that of the duplex DNA (Table 5.1), indicating the 
very weak binding of Se2SAP to the basket-type G-quadruplex structure. In contrast, the 
SPR experiments indicated that Se2SAP showed moderate binding to the chair-type G-
quadruplex formed in the TBA sequence. In comparison to the c-MYC sequence, TBA 
showed an approximate 3-fold increase in the dissociation constant value for Se2SAP and 
a 4-fold decrease in the equilibrium constant value. The SPR results for the binding of 
Se2SAP to the four different G-quadruplex-forming sequences were converted to steady-
state binding isotherm plots and are shown in Figure 5.8. The steady-state isotherms were 
constructed by averaging the observed SPR responses in the steady-state region, and the 
responses were then converted to r, moles of Se2SAP bound per mole of G-quadruplex 
DNA (r = RUobs/RUmax), and plotted against the free Se2SAP concentration in the flow 
solution. The fitting results shown in Figure 5.8 are for the single strong binding site. As 
seen in Table 5.2, the plots clearly indicate the order of binding of Se2SAP to the G-
quadruplex as c-MYC ≥ TetTel »TBA » G2T4, i.e., single-loop hybrid ≥ double-loop 
hybrid » chair-type » basket-type G-quadruplexes.  
Se2SAP Binds Selectively to the Hybrid Conformation of the Human Telomere 
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To date, multiple G-quadruplex structures have been characterized for the human 
telomeric sequence. Wang and Patel reported that a DNA oligonucleotide with a human 
telomeric sequence forms an intramolecular basket-type G-quadruplex structure in the 
presence of Na+ [28]. Basket-type G-quadruplexes have one diagonal and two lateral, or 
edgewise, loop regions, with the guanine columns in an antiparallel arrangement [29]. 
Parkinson et al. reported a solid-state, intramolecular propeller-type G-quadruplex 
structure that forms in the presence of K+ [30]. However, more recent solution-based 
studies suggest that the human telomere forms other structures including a mixed 
parallel/antiparallel hybrid structure [31, 32]. Circular dichroism spectroscopy has been 
used to demonstrate that for the human telomeric d[T2AG3]4 oligonucleotide, Se2SAP 
binds to a hybrid G-quadruplex structure [17]. We provide further experimental evidence 
for the structure-based selectivity of Se2SAP by using SPR under varied salt conditions.  
To quantitatively determine the equilibrium constant and stoichiometry of binding 
of Se2SAP to the 5'-d[AGGG(TTAGGG)3]-3' oligonucleotide under different salt 
conditions, SPR experiments were carried out as described (experimental section). The 
human telomeric oligonucleotide was immobilized in a sensor chip flow cell, and a range 
of Se2SAP concentrations with Na+- or K+-containing buffers were injected to 
quantitatively evaluate the interactions with DNA. The signal in RU was determined as a 
function of time as the compound flow solution passes over a blank flow cell and the 
DNA cell. The signal from the blank flow cell was subtracted from that of the DNA cell 
to provide the final concentration-dependent sensorgrams in Figure 5.9. As flow 
continued, a steady-state plateau was reached in which the rates of compound binding to 
and dissociation from the immobilized DNA were equal. The response values in the 
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steady-state region of the sensorgrams were plotted versus the unbound concentration of 
Se2SAP from the flow solution (Cf) to obtain the binding constants. The stoichiometry of 
binding arose from the RU value approached with increasing Se2SAP concentration. The 
significant difference in the limiting RU value for K+ and Na+ defined the binding 
stoichiometry of 2:1 in Na+ and 1:1 in K+.  
Binding plots were constructed by averaging the observed SPR response in the 
steady-state region, and the responses were plotted against Cf (Figure 5.10). The RU 
versus Cf plots were fitted to binding models with one or two binding sites (Experimental 
Procedures). In the case of Na+, the telomeric G-quadruplex sequence binds two 
molecules of Se2SAP with binding constants that are identical within experimental error, 
K1 = K2 = 4.9 × 106 M-1. In contrast, only one strong binding site with K1 = 1.8 × 107 M-1 
for the binding of Se2SAP with the human telomeric sequence in K+ containing buffer 
was observed. The binding isotherms of Se2SAP in K+ can be fitted to a two-site binding 
model, but the K2 is at least 10 times less than the K1, characteristic of weak, nonspecific 
binding, and cannot be determined accurately. The primary equilibrium constant (K1) 
showed a 4-fold increase in K+ solution compared to Na+, indicating preferential binding 
of Se2SAP with the hybrid structure rather than with the basket structure. Although the 
binding constant in K+ is higher than that in Na+, the fitting results do not show a striking 
visual difference because of the larger second site binding affinity in Na+. The SPR 
results confirm that Se2SAP binds to different G-quadruplex structures formed in the 
human telomeric sequence in the Na+ (basket) and the K+ (hybrid) ions and has a 
preference for the hybrid structure.  
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Conclusions 
Surface plasmon resonance was used to screen a series of metal-substituted and 
expanded porphyrins for binding to c-MYC and human telomere G-quadruplex 
sequences. A diseleno sapphyrin compound, Se2SAP, was identified as the compound 
with the strongest binding to both sequences. SPR not only confirmed the strong binding 
(K = 6.2 × 107 M-1) of Se2SAP to the novel c-MYC G-quadruplex structure but also 
provided solid quantitative information regarding the selectivity of Se2SAP for the 
single-loop hybrid G-quadruplex over the chair- and basket-type G-quadruplex structures 
and duplex DNA. The analysis of the steady-state binding isotherms from SPR further 
established the order of selectivity for binding of Se2SAP to G-quadruplexes, as single-
loop hybrid (c-MYC) ≥ double-loop hybrid (TetTel) » chair-type (TBA) » basket-type 
(G2T4) and duplex DNA (Table 1 and Figure 5.8). Thus, the results from SPR 
experiments confirmed the selective and strong binding of Se2SAP to the c-MYC G-
quadruplex structure in comparison to other G-quadruplex structures (parallel, basket, 
and chair) or duplex DNA. SPR studies with the human telomere further confirm the 
selectivity of Se2SAP for mixed parallel/antiparallel hybrid structures. In the presence of 
Na+, the human telomere adopts a basket structure and Se2SAP binds to this 
conformation with two binding sites, K1 = K2 = 4.9 x 106 M-1. However, in the presence 
of K+, the human telomere forms a mixed parallel/antiparallel hybrid structure and 
Se2SAP binds it with one stronger binding site, K = 1.8 x 107 M-1. The selectivity for 
mixed parallel/antiparallel quadruplex structures exhibited by Se2SAP establishes the 
important principle that it is possible to design molecules that are selective for different 
G-quadruplex DNA structures. 
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Figure 5.1 Structures of (A) TMPyP4, (B) Telomestatin, and (C) G-quartet. 
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Figure 5.2 Structures of metal-substituted porphyrins and expanded porphyrins studied.  
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Figure 5.3 Steady-state binding plots for the modified porphyrins studied with human 
telomeric sequence (top) and c-MYC sequence (bottom) fit to a two-site model. The 
concentration values are for unbound compound concentration in the flow solution. 
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Table 5.1 Equilibrium binding constants for modified porphyrins with human telomere 
and c-MYC sequences obtained by SPR  
 
 
 
 
Compound Human Telomere 
K x 10-6 (M-1) 
 
K1                    K2 
c-MYC 
K x 10-6 (M-1) 
 
K1                              K2 
TMPyP4 
 
3.5 
 
0.37 14 
 
5.4 
Se2Py3 
 
0.57 
 
 1.0 
 
 
S2Py3 
 
2.0  5.3  
S2SAP 
 
1.5 
 
 4.5 
 
 
Se2SAP 
 
10 
 
 62 
 
 
SHPy3 
 
6.9  22  
 
 
All experiments were performed in HEPES buffer containing 200 mM KCl at 25°C. 
Fitting errors due to random point scatter in any experiment are less than ±5%. The 
binding plots for each compound were fit with a two-site model. Only TMPyP4 exhibited 
two strong binding sites. The other compounds exhibited weaker, secondary binding with 
K2 values (not shown) at least ten times lower than K1. 
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Figure 5.4 SPR sensorgrams for binding of Se2SAP to the immobilized G-quadruplex 
formed by a 19-mer c-MYC sequence (top) and CGAATTCG (bottom) as a hairpin 
duplex in HEPES buffer containing 200 mM KCl at 25°C. The c-MYC curves range in 
Se2SAP concentration from 2 nM for the lowest curve to 100 nM for the top curve, and 
for the duplex, they range in Se2SAP concentration from 8 to 100 nM, from bottom to 
top. 
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Figure 5.5 SPR sensorgrams for the binding of Se2SAP to Tetrahymena telomere 
sequence (TetTel). Binding experiments were performed at 25ºC in HEPES buffer 
containing 0.2 M NaCl. The concentration range is from 0.1 to 100 nM. 
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Figure 5.6 SPR sensorgrams for the binding of Se2SAP to thrombin binding aptamer 
(TBA). Binding experiments were performed at 25ºC in HEPES buffer containing 0.2 M 
KCl. The concentration range is from 0.1 to 100 nM. The black solid lines represent the 
results of the global kinetics fit. 
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Figure 5.7 SPR sensorgrams for the binding of Se2SAP to G2T4. Binding experiments 
were performed at 25ºC in HEPES buffer containing 0.2 M KCl. The concentration range 
is from 0.1 to 100 nM. The black solid lines represent the results of a global kinetics fit.  
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Table 5.2 Equilibrium and Dissociation Kinetics Constants for Se2SAP Binding to G-
Quadruplex and Hairpin Duplex DNA determined by SPR 
 
 
DNA K x 10-7 
(M-1) 
kd 
(s-1) 
ka x 10-3 
(M-1s-1) 
c-MYC 6.2 0.0029 1.8 
TetTel 4.2 0.0041 1.7 
TBA 1.4 0.0094 1.3 
G2T4 0.31 0.034 1.1 
hairpin duplex 0.16 >0.2 >3 
 
 
All experiments were performed in HEPES buffer containing 200 mM KCl at 25°C and 
were repeated at least twice with fresh samples. Fitting errors due to random point scatter 
in any experiment are less than ±5%. Experimental errors estimated from reproducibility 
of results are ±10% for K values between 1 x 106 and 2 x 107 M-1 and for kd values 
between 0.1 and 0.001 s-1. Errors increase to ±20% for K values between 3 x 107 and 1 x 
108 M-1. It is difficult to accurately determine kd values that are significantly greater than 
0.1 s-1 by biosensor SPR methods. Because of some adsorption of Se2SAP in the 
biosensor flow system on initial injection, the ka values are difficult to determine directly 
and the values in the table are estimated from K and kd. 
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Figure 5.8 SPR steady-state binding plots. The concentration axis is for Se2SAP in the 
flow solution and is the unbound compound concentration; r represents the moles of 
compound bound per mole of G-quadruplex DNA. The points are for experimental data 
and the lines are the best-fit results for nonlinear least squares application of a single-site 
model to the data. Fitting errors due to random point scatter in any experiments are less 
than ±5%. The equilibrium constants determined from fitting data sets for each DNA are 
collected in Table 5.1. The buffer for all DNAs except TetTel was HEPES with 200 mM 
KCl. TetTel results are for the same buffer but with the KCl replaced by 200 mM NaCl.  
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Figure 5.9 Sensorgrams for Se2SAP binding to the human telomere, d[AG3(T2AG3)3], in 
HEPES buffer containing 100 mM K+ (top) and 100 mM Na+ (bottom). The 
concentration range in both plots is from 0.0 µM to 0.4 µM. 
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Figure 5.10 Direct binding plots for Se2SAP to the human telomere, d[AG3(T2AG3)3], in 
100 mM K+ (black) and 100 mM Na+ (red). The concentration axis is for Se2SAP in the 
flow and is the unbound compound concentration. Direct plot curves from all 
experiments were fitted to a two-site binding model. The agreement in all experiments 
was within ±25% for both K values.  
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Chapter 6 
Binding of Fluoroquinolone Derivatives to Quadruplex DNA 
Introduction 
Topoisomerase II is an enzyme that transiently cuts both strands of double-helical 
DNA, allowing another duplex strand to pass through. In bacteria, this enzyme serves as 
a target for antibacterial agents [1, 2]. In humans, topoisomerase II is a target for anti-
cancer therapies. Fluoroquinolones (Figure 6.1) are a class of well-studied anti-bacterial 
agents that have exhibited activity as bacterial topoisomerase II inhibitors [3, 4]. They 
have large, planar aromatic structures which bind to single-stranded DNA and act by 
trapping the topoisomerase enzyme on the DNA to form a “cleaved complex” [5]. They 
have weak interactions with duplex and quadruplex DNAs [6]. The quinobenzoxazines 
are synthetic analogs of fluoroquinolones with extended ring systems that act as potent 
inhibitors of mammalian topoisomerase II [7]. They bind preferentially to duplex DNA 
by intercalation of one molecule, with another molecule bound externally through 
chelation with two Mg2+ ions. It is likely that the external portion of the complex is 
responsible for the interaction with topoisomerase. A-62176 (Figure 6.1) is a 
fluoroquinobenzoxazine which has shown activity against human tumors in vivo 
including multi-drug resistant lines [8-10]. Because of its limited ability to form π- π 
stacking interactions, it does not bind strongly to G-quadruplexes and is a weak inhibitor 
of telomerase. This compound served as the basis of the design of a subsequent 
generation of fluoroquinophenoxazine and fluoroquinoanthroxazine compounds that were 
designed and synthesized to have selectivity for either topoisomerase II or G-quadruplex 
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interactions (Figure 6.1). It was believed that these compounds would likely bind G-
quadruplex DNA better due to the larger ring systems that can stack better on the G-
quartet surface. QQ58 and FQA-CR were shown to interact with G-quadruplexes, but 
have little activity against topoisomerase II [11, 12]. A stereoisomer of FQA-CR, FQA-
CS was shown to be a potent topoisomerase II inhibitor that has little interaction with G-
quadruplex DNA [12]. The trans FQA isomers (FQA-TR and FQA-TS) were also 
synthesized and studied, but they inhibited topoisomerase II and telomerase to a lesser 
degree than the other compounds [12].  
This work with fluoroquinophenoxazine and fluoroquinoanthroxazine compounds 
served as the basis for the design of a new generation of fluoroquinolone derivatives 
developed by Cylene Pharmaceuticals [13]. One of these compounds, CX-3543 (structure 
not shown for proprietary reasons), demonstrates potent in vivo efficacy against a broad 
range of human tumors with a broad safety window. It is the first quadruplex-interactive 
compound to be evaluated in clinical trials. Currently it is in a Phase I trial of patients 
with advanced solid tumors or lymphomas. So far it has been well tolerated in humans 
with no toxicity to bone marrow, heart, liver or kidneys. This trial will determine the 
maximum tolerated dose (MTD), identify dose limiting toxicities (DLT), and establish 
the recommended dose for future Phase II studies.  
CX-3543 was designed to selectively bind to the structural class of parallel 
quadruplexes as found in the G-rich strand of the promoter region of the c-MYC 
oncogene. However, intracellularly, CX-3543 demonstrates no direct effect on c-MYC 
transcription. It is believed that CX 3543 may be targeting a different G-quadruplex 
  202   
structure, possibly the telomere or the ribosomal DNA template. Stabilization of the 
quadruplex conformation of the rDNA template would disrupt the interaction between 
nucleolin and the template. This would inhibit rRNA biogenesis in cancer cells, inducing 
apoptosis. Surface plasmon resonance (SPR) was attempted with CX 3546 in order to 
quantitatively measure its binding interactions with a series of quadruplex-forming DNA 
sequences, in order to gain insight into which quadruplex sequence it is targeting. Due to 
solubility problems, a full set of sensorgrams could not be obtained with this compound. 
A limited amount of kinetics data was collected, but the data had problems with errors 
and reproducibility. CX 2406 (structure not yet disclosed) is a second-generation Cylene 
compound that is closely related in structure to CX 3543. However, it exists as a 
dimesylate salt, making it more water-soluble than CX 3543. Therefore CX 2406 was 
used as a model system for studying CX 3543, allowing a full range of SPR experiments 
with six different quaduplex DNAs and one duplex DNA to be performed. In addition, 
SPR binding studies were performed with the earlier generation fluoroquinophenoxazine 
and fluoroquinoanthroxazine compounds A-62176, QQ58, FQA-CR, FQA-CS, FQA-TR 
and FQA-TS as a basis for comparison. 
Materials and Methods 
Sample Preparation 
The oligonucleotides 5’-biotin-d[AG3(T2AG3)3], 5’-biotin-d(AG3TG4AG3TG4A), 
5’-biotin-d(CGAATTCG), 5’-biotin-d[(G2T4)3], 5’-biotin-d[(T2G4)4], and 5’-biotin-
d(G2T2G2TGTG2T2G2) were purchased with HPLC purification and mass spectrometry 
characterization from Midland Certified Reagent Company. Stock solutions containing 1 
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mM of each compound were prepared in double distilled water or DMSO and diluted to 
working concentrations immediately before use with buffer. A-62176, FQA-CS, FQA-
CR, FQA-TR, FQA-TS and QQ58 were synthesized by Dr. Laurence H. Hurley’s group 
at the University of Arizona. CX 3546 and CX 2406 were synthesized by Cylene 
Pharmaceuticals (San Diego, CA). 
Immobilization of DNA and Biosensor SPR Experiments 
Biosensor SPR experiments were performed with a four-channel BIAcore 2000 
optical biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips (BIAcore 
SA with linked streptavidin). All DNA samples, for either duplex- or quadruplex-binding 
experiments, were used as single strands (fold-back structures) to prevent dissociation in 
the SPR flow system. The concentration in all cases refers to the strand concentration, 
which is also the duplex or quadruplex concentration. The chips were prepared for use by 
conditioning with three to five consecutive 1 min injections of 1 M NaCl in 50 mM 
NaOH followed by extensive washing with buffer. 5'-Biotinylated DNA samples (25 nM) 
in HBS buffer were immobilized on the flow cell surface by noncovalent capture as 
previously described. Three flow cells were used to immobilize DNA oligomer samples, 
and a fourth cell was left blank as a control. Interaction analysis was performed by using 
both kinetics and steady-state methods with multiple injections of different compound 
concentrations over the immobilized DNA surface at 25 ºC. DNA-binding experiments 
were performed in sterile filtered and degassed HBS buffers: 0.01 M HEPES, (pH 7.4), 3 
mM EDTA, and 0.005% surfactant P20 with either 0.1 M KCl or NaCl. Compound 
solutions were prepared in the desired buffer by serial dilutions from stock solution and 
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injected from 7 mm plastic vials with pierceable plastic crimp caps (BIAcore, Inc.) at a 
flow rate of 25 µL/min for steady state experiments. To remove any remaining bound 
compound after the dissociation phase of the sensorgram, a low-pH glycine regeneration 
buffer was used (10 mM glycine at pH 2). The baseline was then reestablished, and the 
next compound concentration sample was injected.  
The instrument response (RU) in the steady-state region is proportional to the 
amount of bound drug and was typically determined by linear averaging over a 10-20 s or 
longer time span, depending on the length of the steady-state plateau. The predicted 
maximum response per bound compound in the steady-state region (RUmax) was 
determined from the DNA molecular weight, the amount of DNA on the flow cell, the 
compound molecular weight, and the refractive index gradient ratio of the compound and 
DNA, as previously described. The number of binding sites was estimated fitting plots of 
RU versus Cfree. These methods can also be used to determine an empirical RUmax value. 
The RUmax value is required to convert the observed response (RU) to the standard 
binding parameter r (moles of drug bound per moles of DNA hairpin) 
r = RU/RUmax 
 
which is useful for comparison of a compound binding to different DNAs. To obtain the 
affinity constants, the data were fitted to the following interaction model using 
Kaleidagraph for nonlinear least-squares optimization of the binding parameters: 
 
r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2) 
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where K1 and K2 are equilibrium constants for two types of binding sites and Cfree is the 
concentration of the compound in equilibrium with the complex and is fixed by the 
concentration in the flow solution. For a single dominant binding site model, K2 is equal 
to zero. Errors in fitting two K values within any experiment were ±10%, while errors in 
K values in replicate experiments were ±25%. Errors in fitting results that required only a 
single K value were ±10%. 
Kinetics data were obtained for the human telomeric sequence, the c-MYC 
sequence and the Tetrahymena telomere sequence in buffer containing 100 mM KCl. 
After injection of the compound and prior to reinjection of buffer, the association kinetics 
of compound binding to immobilized DNA were monitored, and after reinjection of 
buffer the dissociation kinetics were determined. To minimize possible mass transport 
effects, SPR kinetics experiments were conducted at flow rates of 50-100 µL/min using a 
different sensor chip with low surface densities of immobilized DNA. Global fitting 
using a one-site model (BIA Evaluation Software, BIAcore, Inc.) of the association and 
dissociation curves was done in a concentration range where the compound binds 
significantly only to the strongest binding site in order to obtain the association rate 
constant, ka, and the dissociation rate constant, kd, for the first binding site for these 
complexes. For the compounds that did not reach steady state at low concentrations, a fit 
of the kinetics data was used to estimate the RU at equilibrium for the lower 
concentration region in order to determine a steady-state binding constant. 
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Results and Discussion 
Human Telomeric DNA is the likely target for CX 2406 
SPR was used to quantitatively evaluate the interaction between CX 2406 and a 
series of quadruplex-forming DNA sequences in order to provide insight into the 
selectivity of this compound for different types of quadruplexes. A hairpin duplex 
sequence was also studied in order to evaluate the selectivity of CX 2406 for quadruplex 
DNA vs. duplex DNA. The sequences, d[AG3(T2AG3)3] (HTel), d(AG3TG4AG3TG4A) 
(c-MYC), d(CGAATTCG) (duplex), d[(G2T4)3] (G2T4), d[(T2G4)4] (TetTel), and 
d(G2T2G2TGTG2T2G2) (TBA) were immobilized using two different SPR sensor chips. 
For all DNA sequences, the sensorgrams were obtained using buffer containing 100 mM 
KCl. Because the conformation of the human telomere is dependent on the type of cation 
present, sensorgrams for the binding of CX 2406 to the HTel sequence were also 
obtained in buffer containing 100 mM NaCl. A range of CX 2406 concentrations (0.1 nM 
to 90 nM) were injected to quantitatively evaluate the interaction with the DNA. Blank 
injections with running buffer were also performed, and the resulting sensorgrams were 
subtracted from the compound sensorgrams to obtain the final concentration-dependent 
graphs (Shown in Figures 6.2-6.4). The plot of RU versus the unbound concentration of 
each of the compounds was fitted to a two-site binding model (Experimental Section). 
The response values in the steady-state region of the sensorgrams were converted to r and 
plotted versus the unbound concentration (Cf) of CX 2406 in the flow solution (Figure 
6.5). The equilibrium binding constants (K values) are shown for each compound in 
Table 6.1.  
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Because the sensorgrams had not reached steady state in the lower concentrations 
for the HTel (in KCl), c-MYC, and TetTel sequences, binding plots that use this data may 
underestimate the K values for CX 2406 binding with these DNAs. To obtain a more 
accurate value of the binding constant for the first strong binding site (K1) with these 
three DNAs, a one-site global kinetics fit was performed for the lower concentration 
ranges of sensorgrams for CX 2406 with each of these DNAs (Figure 6.6). These values 
are shown in Table 6.1. The steady-state response at low concentrations was calculated 
from a fit of these kinetics curves and used to calculate the steady-state binding constants 
for these DNAs. 
Fits of the binding data show that CX 2406 binds the strongest to the human 
telomeric sequence in KCl. The first, strong binding site has a kinetics binding constant 
of K1 = 2.8 x 108 M-1. This is among the highest binding constants reported for small 
molecule binding to human telomeric DNA to date [14].Several quadruplex structures 
have been proposed for the human telomere in potassium. However, recent studies 
suggest that it likely forms a mixed parallel/antiparallel hybrid structures under these salt 
conditions [15, 16]. CX 2406 also exhibits strong binding with TetTel (K1 = 2.2 x 108 M-
1). TetTel also has been shown by NMR to form a mixed parallel/antiparallel quadruplex 
structure [17]. CX 2406 also binds strongly (K1 = 1.7 x 108 M-1) to the c-MYC sequence, 
but this sequence has been ruled out as a target for the biological action for this class of 
compounds. The binding of this compound is lower to the TBA sequence, which forms 
an antiparallel chair-type quadruplex [18], G2T4, which forms an antiparallel basket 
quadruplex [19, 20] and HTel in the presence of sodium, which also forms a basket-type 
structure [21].   
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These results suggest that CX 2406 may be selective for the mixed 
parallel/antiparallel hybrid type of quadruplex structure, and not the parallel quadruplex 
structure formed by c-MYC that it was initially designed to target.  
CX 2406 is Selective for Quadruplex Over Duplex DNA 
These results show also that CX 2406 is selective for quadruplex over duplex 
DNA. CX 2406 binds to two equivalent sites of the duplex DNA with K1 = K2 = 1.1 x 107 
M-1. Although this binding constant is very high, the binding constant for the strong site 
of the human telomere as determined by kinetics is 25 times higher (2.8 x 108 M-1). As 
seen from the sensorgrams of CX 2406 with duplex DNA, it also has very fast 
dissociation kinetics. This high degree of selectivity for quadruplex over duplex DNA is 
consistent with the absence of cytotoxicity seen so far with CX 3543 in the Phase I 
clinical trials.  
CX 2406 Shows Improved Binding Over Other Fluoroquinolone Derivatives 
To quantitatively compare quadruplex binding affinity of CX 2406 to that of the 
previous generation of modified fluoroquinolones, SPR binding studies were performed 
with A-62176, QQ58, FQA-CR, FQA-CS, FQA-TR and FQA-TS. A sensor chip 
containing HTel, c-MYC and the duplex sequence was used. For all compounds, the 
amount of binding with each of the DNA sequences was too low to be measured using 
SPR. Sensorgrams for FQA-CR, the compound from this set that was previously shown 
to have the strongest degree of interaction with quadruplex DNA [12], are shown in 
Figure 6.7 as an example. 
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Conclusion 
CX 3543 is a fluoroquinolone derivative that was initially designed to bind 
specifically to the quadruplex structure formed by the G-rich strand of the c-MYC 
oncogene. Although this compound has shown potent anti-cancer activity against a broad 
range of tumors, evidence suggests that c-MYC is not actually the biological target. A 
CX 3543 derivative, CX 2406, was evaluated against different quadruplex-forming DNA 
sequences using SPR. It exhibited extremely high binding with the human telomere (2.8 x 
108 M-1), which suggests that this sequence might actually be the target, and that its mode 
of action is telomerase inhibition. CX 2406 also was found to have a 25-fold selectivity 
for the human telomere over duplex DNA, consistent with the absence of cytotoxic side 
effects seen so far in patients receiving CX 3543 in Phase I clinical trials. CX 2406 also 
binds much stronger to quadruplex sequences than the fluoroquinolone compounds that 
CX 2406 and CX 3543 were based on. This suggests that the structural modifications that 
differentiate CX 2406 and CX 3543 from the earlier compounds play a very significant 
role in the selective recognition of quadruplex DNA. 
The identification of the human telomere as the probable quadruplex target for 
CX 2406 (and thus CX 3543), provides evidence that specific quadruplex structures can 
be targeted selectively. Knowing the structure of the target will also aid in the design and 
evaluation of new compounds that may target this sequence with even higher affinity and 
selectivity. 
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Figure 6.1 Structures of fluoroquinolone and fluoroquinolone derivatives 
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Figure 6.2 SPR sensorgrams for binding of CX 2406 to the immobilized G-quadruplex 
formed by c-MYC (top), human telomere (middle) and duplex DNA (bottom) as a hairpin 
dimer in HEPES buffer containing 100 mM KCl at 25°C. Each sensorgram ranges in 
concentration from 0.1 nM for the lowest curve to 90 nM for the top curve. 
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Figure 6.3 SPR sensorgrams for binding of CX 2406 to the immobilized G-quadruplex 
formed by G2T4 (top), and TetTel (bottom) in HEPES buffer containing 100 mM KCl at 
25°C. Each sensorgram ranges in concentration from 0.1 nM for the lowest curve to 90 
nM for the top curve. 
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Figure 6.4 SPR sensorgrams for binding of CX 2406 to the immobilized G-quadruplex 
formed by TBA (top) in HEPES buffer containing 100 mM KCl, and human telomere 
DNA (bottom) in HEPES buffer containing 100 mM NaCl at 25°C. Each sensorgram 
ranges in concentration from 0.1 nM for the lowest curve to 90 nM for the top curve. 
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Figure 6.5 SPR steady-state binding plots for CX 2406. The concentration axis is for CX 
2406 in the flow solution and is the unbound compound concentration; r represents the 
moles of compound bound per mole of G-quadruplex DNA. The points are for 
experimental data and the lines are the best-fit results for nonlinear least squares 
application of a two-site model to the data. Fitting errors due to random point scatter in 
any experiments are less than ±5%. The equilibrium constants determined from fitting 
data sets for each DNA are collected in Table 6.1. All experiments were performed in 
HEPES buffer containing 100 mM KCl at 25°C except HTel (Na+) which was performed 
in 100 mM NaCl. 
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Table 6.1 Steady-State and Kinetics Binding Constants for CX 2406 as Determined by 
SPR 
 
DNA Steady-State 
Binding Constants 
 
K1 x 10-6  K2 x 10-6  
(M-1)          (M-1)    
 
Kinetics Binding Constants 
 
 
K1 x 10-6         ka                    kd 
(M-1)          (M-1s-1)               (s-1) 
 
HTel (K+) 
 
140 2.2 280 8.3 x 105 3.0 x 10-3 
HTel (Na+) 
 
9.8 1.4    
Duplex 
 
11 11    
TetTel 
 
160 12 220 2.0 x 105
  
8.8 x 10-4 
TBA 
 
6.1 1.7    
c-MYC 
 
190 12 170 3.3 x 105 1.9 x 10-3  
G2T4 
 
<0.1      
 
All experiments were performed in HEPES buffer containing 100 mM KCl at 25°C 
except HTel (Na+) which was performed in 100 mM NaCl. Fitting errors due to random 
point scatter in any experiment are less than ±5%. The steady state binding plots for each 
compound were fit with a two-site model. Kinetics data was fit with a one-site global 
fitting model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  216   
 
-10
-5
0
5
10
15
-200 0 200 400 600 800 1000 1200
RU
R
es
po
ns
e
sTim e  
 
-10
-5
0
5
10
15
-200 0 200 400 600 800 1000 1200
Tim e s
R
es
po
ns
e
RU
 
-6
-4
-2
0
2
4
6
8
10
12
14
-200 0 200 400 600 800 1000 1200 1400
Tim e s
R
es
po
ns
e
RU
 
Figure 6.6 SPR sensorgrams for binding of CX 2406 to Htel (top), c-MYC (middle) and 
TetTel (bottom). Concentration ranges from 0.1 nM to10 nM. The black solid curves 
represent a 1:1 global kinetics fit.  
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Figure 6.7 SPR sensorgrams for binding of FQA-CR to the immobilized G-quadruplex 
formed by HTel (top) and c-MYC (bottom) in HEPES buffer containing 100 mM KCl at 
25°C. Each sensorgram ranges in concentration from 0.1 nM for the lowest curve to 0.2 
µM for the top curve. 
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